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CHAPTER ONE
INTRODUCTION
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1.1 INTRODUCTION
"As medical means can do nothing more 
than relieve the symptoms of cancer of 
the stomach, and as surgery holds out 
the only hope of relief or cure 
moreover as the earlier these cases are 
seen by the surgeon the greater is the 
probability of real good being done - it 
would seem to me that in every case 
where cancer of the stomach is suspected 
the question of surgical treatment 
should be considered at a much earlier 
period than is now the custom."
A.Mayo Robson,FRCS,1900
This is an extract from a lecture delivered 
by A.Mayo Robson to the Royal college of Surgeons 
of England at the turn of this century (1). How 
relevant are these comments 9 decades later? In 
this thesis an attempt will be made to answer this 
question by examining the present natural history 
of gastric cancer and assessing the current 
results of surgery and chemotherapy. However, the 
emphasis will be on the role of chemotherapy in 
the treatment of gastric cancer because as a
20
medical oncologist this is the area where 
make the most relevant contribution.
can
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1.2 INCIDENCE AND AETIOLOGY
The most recent statistics from England and 
Wales show that 11,553 cases of stomach cancer 
were registered in 1983 (Table 1.1) (2). It is the
third most common cause of cancer deaths in males 
and the fourth most common cause of cancer deaths 
in females (3). There is a marked male 
preponderance with a male to female ratio of 2:1 
and it is more common among lower socioeconomic 
groups (2). During the past 50 years there has 
been a steady, unexplained decline in the number 
of cases affecting both sexes (4) but the crude 5 
year survival has remained between 7-11% (5). In
Scotland the number of cases of gastric cancer has 
also decreased during the past 50 years (6). The 
average incidence is similar to England and Wales 
but there are some areas where the incidence is up 
to 1.5 times the national average. These are 
generally the industrial areas such as Glasgow and 
Dundee with a lower incidence in the rural areas 
(6) .
On a worldwide scale, the incidence of 
gastric cancer varies considerably (Table 1.2) 
(7).The incidence in Japan exceeds any other 
country and is more than 2.5 times that of the 
United Kingdom and 9 times that of the U.S.A..
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Site Description Number %*
a) Males 
All sites
(ICD 140-208) 100,645 100
Trachea, bronchus 
and lung 26,403 26
Skin other than melanoma 11,317 11
Prostate 9,127 9
Stomach 7,060 7
Bladder 6,683 7
Colon 6,488 6
Rectum, rectosigmoid 
junction and anus 5,171 5
Pancreas 2,881 3
Oesophagus 2,294 2
Kidney and other 
unspecified urinary
organs 1,894 2
Others 21,327 21
b) Females 
All sites
(ICD 140-208) 97,604 100
Breast 21,297 22
Skin other than melanoma 10,419 11
Trachea, bronchus 
and lung 9,475 10
Colon 8,124 8
Ovary and other 
uterine adnexa 4,521 5
Stomach 4,493 5
rectum, rectosigmoid 
junction and anus 4,329 4
Cervix uteri 3,875 4
Body of uterus 3,346 3
Pancreas 2,752 3
Other 24,973 2 6
*The sum of percentages for individual sites do 
not always add to 100 because of rounding.
Table 1.1 The ten most common malignant sites 
registered in England and Wales in 1983 
with the percentage that each of the ten 
sites forms of all sites
Country Males Females
Japan 50.4 25.
Chile 46.0 23.
Hungary 33.4 15.
Austria 26.1 13.
Italy 23.4 11.
Spain 21.4 11.
Scotland 18.8 9.
England and Wales 18.1 8.
Mauritius 16.3 7.
Sweden 13.4 7.
France 13.1 6.
Canada 10.5 4.
USA 6.4 3.
Nicaragua 0.1 0.
4
4
8
6
2
1
2
1
4
0
0
8
13
4
Table 1.2 Age-adjusted death rates for cancer 
the stomach in the World
Japanese migrants to the U.S.A. have a lower 
incidence of stomach cancer but it remains 5 times 
that of the indigenous population (8). The marked 
inter-country variation in the incidence of 
gastric cancer, and the studies of migrant 
populations have implicated environmental factors 
in its aetiology. The most important of these is 
thought to be diet but other factors such as 
exposure to coal dust or asbestos are also
relevant (9).
There have been a number of studies which 
have attempted to identify the dietary 
constituents which lead to an increased risk of 
gastric cancer (10-15). The results have been
conflicting. For Japanese migrants to Hawaii the
ingestion of salted and dried fish was found to be
a strong risk factor (10) but this was not 
confirmed in a further study from Japan (11). 
Similarly in South Louisiana, smoked foods and 
home cured meat were associated with an increased 
risk of gastric cancer in the black population but 
not in the white (12). One recent study from
Greece identified pasta beans and nuts (13) and 
another from Canada identified chocolate and 
carbohydrate as risk factors (14). In Columbia, 
which has one of the highest incidences of gastric 
cancer outside Japan, people from areas with a
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high incidence of gastric cancer were found to eat 
fava beans in far larger amounts than equivalent 
groups from low incidence areas (15). However the 
only consistent finding from all of these studies 
was the protective effect of the ingestion of 
vegetables, particularly lettuce and citrus fruits 
(10-15). In Scotland, there have not been any 
studies of diet and gastric cancer but the Scots 
do eat up to 50% more processed foods than the 
English and this may be related to the higher 
incidence of the tumour in certain areas(6). 
Alcohol and cigarettes have no proven link with 
the developement of gastric cancer (10-15).
On the basis of some of these epidemio­
logical data, nitrites have been implicated in the 
aetiology of gastric cancer. Nitrites are used as 
a preservative and a colouring agent in a variety 
of fish and meat products especially home-cured 
meats, dried fish and sausages. Also, nitrates in 
the diet can be converted to nitrites by 
bacterial action in the food or in the stomach 
(16). Dietary nitrates are mainly derived from 
crop fertiliser. They are taken up by the crops, 
and may also contaminate fresh water supplies. 
Nitrates are also used in the process of recycling 
sewage. These factors have led to a general 
increase in the amount of dietary nitrate in the
24
past 20 years (17). Nitrites can also interact 
with Japanese soy sauce (18) and with fava beans 
to make them mutagenic (19).
One possible mechanism for the developement 
of gastric cancer which incorporates these 
nitrite/nitrate data was suggested by Correa et al 
(20). In this hypothesis gastric atrophy played a 
key role by leading to a reduction in gastric acid 
secretion and permitting bacterial colonisation 
of the stomach; this would not be possible in an 
acid environment. These bacteria, it was 
postulated, could reduce dietary nitrate to 
nitrite and form N-nitroso compounds through the 
nitrosation of dietary amines. N-nitroso compounds 
are known to be carcinogenic in animals (21) and 
could therefore act on the atrophic gastric mucosa 
causing intestinal metaplasia, dysplasia and 
ultimately cancer.
It has been suggested that the decline of 
gastric cancer in the U.S.A. and the U.K. is 
linked to more widespread refrigeration of 
foodstuffs with a resultant reduction in the use 
of nitrites. In the USA during the last 50 years 
there has been a 75% reduction in the use of 
nitrites in meat to prevent botulism (22) . However 
2 studies from the United Kingdom failed to show a 
positive association between nitrate in the
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drinking water (23) or in the saliva (24) and 
gastric cancer. Levels of salivary nitrate, which 
are taken to be a good marker of the dietary 
intake of nitrate, showed an inverse correlation 
with the risk of developing gastric cancer (24). 
These findings cast doubt on the importance of 
nitrates as a factor in the developement of 
gastric cancer. Nevertheless, it should be 
emphasised that in the U.K. the largest proportion 
of dietary nitrate is derived from vegetables and 
that since these are abundant in vitamin C, they 
may prevent the formation of carcinogenic N- 
nitroso compounds by blocking the chemical 
reaction between nitrites and dietary amines in 
the stomach (25).
A high intake of salt may also be relevant 
to the developement of gastric cancer. Salt has 
been shown to increase the uptake by the stomach 
of carcinogens in an animal model (26). Thus, in 
man, the salt in dried fish and other cured meats 
may be an important prerequisite to the 
carcinogenic effects of nitrites in the diet. The 
balance between dietary nitrite, ascorbic acid and 
nitrate is clearly of major importance and its 
complex interrelationship could account for the 
difficulties which still exist in this area of 
epidemiology.
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However, there is other evidence favouring 
the Correa hypothesis. Conditions such as 
pernicious anaemia (27,28), hypogammaglobulinaemia 
(29) and gastric surgery for peptic ulcer (30,31) 
are associated with hypochlorhydria and predispose 
to gastric cancer. In a Scandinavian study, 10 
(8%) of 123 patients with pernicious anaemia 
screened endoscopically were found to have gastric 
neoplasms. Five were carcinoid, 4 adenocarcinoma 
and 1 an adenomatous polyp (27). It has also been 
shown that the gastric juice of these patients 
contains bacteria capable of reducing nitrate to 
nitrite (32) . Nevertheless, a recent study of the 
gastric aspirate from 3 groups of patients - 1
with pernicious anaemia, 1 following polya- 
gastrectomy and a control group, whilst confirming 
these findings, failed to show a direct 
correlation between an alkaline pH and an increase 
in the production of nitrosamines (16). Indeed the 
reverse applied - there was a definite trend in 
favour of increased nitrosamine production at an 
acid pH (16). These results suggest the formation 
of N-nitroso compounds in the stomach is more 
likely to occur at an acid pH which favours the 
chemical reaction between nitrites and amines
(33), rather than at an alkaline pH which favours 
bacterial colonisation but not necessarily
27
nitrosation.
These results also imply that the Correa 
model for carcinogens in the stomach (20) is not 
totally accurate. Bacterial colonisation in an 
alkaline pH may not be an essential step. It could 
well be that the achlorhydria is a marker for 
abnormal gastric mucosa, such as the atrophic 
gastritis associated with aging or pernicious 
anaemia, and it is this alteration in the mucosal 
barrier rather than the bacterial colonisation 
which is important. Similarly, after gastric 
surgery patients develop dysplastic changes in the 
residual gastric mucosa as a result of bile reflux
(34) which may predispose to gastric cancer
28
1.3 PATHOLOGY
Adenocarcinoma of the stomach accounts for 
97% of gastric malignancies. There are several 
histological classifications of this tumour in 
current use. The classification devised by the 
World Health Organisation (WHO) recognises 
tubular, papillary, mucinous and signet ring forms 
of gastric cancer (35). It has not gained wide 
acceptance partly because many tumours have a 
mixture of more than 1 type, especially the 
tubular and papillary forms, but also because the 
4 histological groups do not correlate well with 
known epidemiological data.
The most widely used classification was 
proposed by Lauren in 1965 (36). Lauren described 
2 basic types of gastric cancer - intestinal and 
diffuse. The intestinal type is characterised by 
cells which grow in a tubular arrangement similar 
to small intestinal epithelium. They commonly have 
a striated border and are very cohesive, expanding 
into surrounding normal tissue in a well circum­
scribed fashion. There is little fibrous tissue 
reaction but often an inflammatory cell 
infiltrate. In the diffuse type the cells are 
usually single or arranged in indian file and 
infiltrate diffusely into surrounding tissue.
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These cells may be devoid of cytoplasm or contain 
much cytoplasm leading to the so-called signet 
ring cell, where the nucleus is pushed to the side 
of the cell by the cytoplasm. There is usually a 
marked stromal reaction. However, in a consider­
able proportion of cases, approximately 15% 
(37,38), there is a mixture of intestinal and 
diffuse forms and in some reviews it has not been 
possible to classify a further 25% of cases (38).
It has been shown that these 2 histological 
types of gastric cancer, intestinal and diffuse, 
appear to have a distinctive aetiology (37) . The 
diffuse type is taken to be the "endemic" form of 
gastric cancer. It affects both sexes equally and 
is associated with blood group A (37) and younger 
age groups (39,40). It appears to have a strong 
hereditary basis and has a similar incidence in 
high and low incidence areas (37,41). On the other 
hand the intestinal type is the "epidemic" form of 
gastric cancer (37,41). It is more common in males 
with a 2:1 male female ratio and is the most usual 
form of gastric cancer in the elderly (43) . In 
countries with a high incidence of gastric cancer 
such as Japan, the increased number of cases are 
mainly of the intestinal type (37,41). These 
features point towards a strong environmental 
component in the developement of intestinal type
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of gastric cancer. However, it has not always been 
possible to demonstrate such a close correlation 
between the 2 different histological subtypes and 
these features. A recent report from the U.K. 
showed the reverse; there was a higher incidence 
of diffuse gastric cancer in the high risk areas 
for gastric cancer (38). One possible reason for 
this inconsistency is the heterogenous nature of 
the histology. In reality, the architecture of 
these tumours often have a mixture intestinal and 
diffuse forms and morphologically, commonly 
consist of both well and poorly differentiated 
cells, which must make histological assessment 
extremely difficult.
Kubo suggested that well differentiated 
tumours tended to be intestinal and poorly 
differentiated diffuse (43), and that these 
morphological characteristics are of more 
importance than the pattern of growth. Using this 
simple classification in Japan and New Zealand, he 
was unable to show any of the usual demographic 
and epidemiological correlations of the Lauren 
classification (44,45).
Ming has proposed a classification for 
gastric cancer with 2 histological categories; an 
expanding type and an infiltrating type (46). This 
classification, based on an analysis of 171
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gastric carcinomas, has many similarities to that 
of Lauren, with the expanding type corresponding 
to intestinal type and infiltrating type 
corresponding to the diffuse type. Within the 
pattern of expanding or infiltrating types the 
cells can be well differentiated, poorly 
differentiated or undifferentiated. Ming also 
noted that age and sex distribution of expanding 
and infiltrating types were similar to the 2 
histological subtypes of Lauren. Histologically 
the expanding type was commonly associated with 
intestinal dysplasia, which was rare with the 
infiltrating type.
The expanding type of gastric cancer 
constituted 67% of all cases. Of the expanding 
tumours 63% were fungating, 20% ulcerated, 10% 
polypoid, 4% superficial and 3% diffuse. The 
infiltrative carcinoma was diffuse in 68%, 
ulcerated in 27% and fungating in 5% of cases. 
Therefore, the histological type has a significant 
influence on the macroscopic appearance of the 
tumour. The infiltrative carcinoma with a diffuse 
macroscopic appearance gives rise to 1linitis 
plastica1 or leather bottle stomach. The Ming 
classification does appear to have some merit 
although it offers relatively little advantage 
over the Lauren classification.
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It is most important that a histological 
classification should be clinically and 
biologically relevant. Despite the obvious 
difficulties in classifying a proportion of cases, 
the Lauren classification is the closest to 
satisfing these criteria. Patients with the 
intestinal type of gastric cancer have a better 
prognosis than those with the diffuse type, 
independant of the type of surgical treatment
(47). Also, with the the diffuse type microscopic 
infiltration occurs beyond the macroscopic 
boundary of the tumour therefore it is recommended 
that the surgical resection margins for diffuse 
tumours shoud be 5cm compared to the 2cm margin 
for intestinal tumours. Taking these factors and 
the epidemiological data into account I would 
suggest, where possible, the Lauren classification 
of gastric cancer should de used.
The most common sites for gastric cancer are 
the pyloris and pyloric antrum which account for 
70% of cases. Carcinoma of the proximal third of 
the stomach and lower oesophagus now constitute up 
to 30% of cases compared to 15-20% 3 0 years ago
(48). This change in the pattern of distribution 
may be related to the unique association between 
carcinoma of the cardia and lower oesophagus with 
Barrett's oesophagus (49). Thus the apparent
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increase of carcinoma at these sites is due to a 
relative decline of carcinoma of the pyloris and 
pyloric antrum.
Barrett's oesophagus is characterised by a 
shifting of the squamo-columnar junction to at 
least 3cm above the lower most part of the 
oesophagus. Within the columnar epithelium there 
is usually gastric parietal and chief cells, 
junctional epithelium and epithelium which 
resembles intestinal mucosa with an abundance of 
mucous secreting glands (50,51). Epithelial 
dysplasia and carcinoma in situ are well described 
in Barrett's oesophagus (52,53) and result in it 
being a pre-malignant condition (52). Up to 86% of 
oesophageal adenocarcinoma are thought to arise in 
Barrett's oesophagus (52) and carcinoma is found 
in 7 - 46% of Barrett's oesophagus at diagnosis 
(53). The precise aetiology of Barrett's 
oesophagus is not established (53) although it is 
likely to be related to reflux of the gastric 
contents. Between 2 - 11% of patients with reflux 
oesophagitis develop Barrett's oesophagus (53) and 
a proportion of these will ultimately develop 
malignant change.
Efforts to ameliorate the risks of 
malignancy have produced the proponents of radical 
anti-reflux surgery because this is known to
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reverse the epithelial change whereas medical 
treatment does not (55). However, since the risk 
of developing cancer in Barrett's oesophagus may 
be as low as 1 in 175 patient years (56), and the 
average age of patients with Barrett's oesophagus 
is 60 years, the decision regarding surgery is not 
clear-cut.
Predicting the patient most likely to 
develop malignant change within Barrett's 
oesophagus has been difficult. At the present time 
regular endoscopy for patients with severe 
dysplasia is appropriate. However, more sensitive 
markers are required. In the future, by examining 
endoscopic biopsies with oncogene probes such as 
c-Ha-ras p21, which is overexpressed in gastric 
carcinoma (57), it may be possible to detect those 
patients with Barrett's oesophagus at a high risk 
of developing malignancy.
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1.4 MOLECULAR BIOLOGY
During the past 10 years there have been 
enormous advances in our understanding of the 
molecular biology of cancer. The learning curve 
seems to be exponential as we unravel the complex 
interrelationship between cellular oncogenes, 
viral oncogenes, polypeptide growth factors and 
cancer (58-61).
The proto-oncogenes are genes present in 
normal mammalian cells which are homologous with 
the viral genes responsible for the tumourogenic 
properties of RNA tumour viruses. They are also 
known as cellular oncogenes (59). In normal cells 
they are responsible for growth and maturation but 
when transferred to cell lines (transfection) they 
can promote the development of tumours. In 
addition, oncogenes are overexpressed in a variety 
of solid tumours and it has therefore been 
postulated that they are an integral part of the 
mechanism of carcinogenesis (58.59)
A number of oncogenes have now been 
identified in gastric cancer and gastric cancer 
cell lines. These include the genes c-Ha-ras, c- 
myc and c-erbB-2 (57,61-65). The c-Ha-ras p21 gene 
was found to have enhanced expression relative to 
normal tissues in a series of primary stomach
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cancers and was also found in intermediate amounts 
in areas of dysplastic gastric mucosa (57). There 
was no correlation between tumour differentiation 
or depth of invasion and expression of c-Ha-ras 
although there was a tendancy for more advanced 
tumours to express large amounts of c-Ha-ras (57). 
The presence of c-Ha-ras was demostrated by in 
situ hybridisation using a monoclonal antibody to 
the oncogene on frozen and paraffin sections. 
Clearly this work needs further evaluation because 
it may have diagnostic and prognostic implications 
for the future. In addition the activation of the 
c-Ha-ras oncogene in a gastric cancer cell line 
was associated with a point mutation of the 12th 
codon (guanine to thymine) and this may be one of 
the ways in which the gene becomes oncogenic (62).
The c-erbB-2 oncogene is also amplified in 
gastric cancer. This oncogene codes for a protein 
which is similar to epidermal growth factor (EGF) 
receptor (65). The c-erbB-1 oncogene codes for EGF 
receptor and the possession of EGF receptor is 
known to be a poor prognostic factor in breast 
cancer (66). It is therefore of particular 
interest that EGF has also been found in primary 
gastric cancers and that the prognosis was worse 
for patients whose tumours elaborated EGF (67). 
The promoter regions for c-erbB-1 (68) and c-erbB-
37
2 (69) have recently been characterized. These 
areas regulate the production of receptors by the 
gene and therefore are targets for highly specific 
monoclonal antibody therapy. If the monoclonal 
antibody could be internalised within the nucleus 
without degradation it could effectively switch 
off receptor production and possibly control 
tumour growth.
The potential use of molecular biology in 
the diagnosis and treatment of cancer is enormous. 
However there is a caveat; oncogene over 
expression may only be an epiphenomenon - a marker 
of rapidly growing cells - and as such several 
steps removed from the fundamental initiation of 
carcinogenesis. Therefore it is wise to remain 
somewhat circumspect about their future role.
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1.5 NATURAL HISTORY
In Europe and the USA gastric cancer 
presents late in its natural history. By the time 
of diagnosis the majority of patients have locally 
advanced disease or have evidence of metastases. 
Presenting symptoms related to gastric cancer are 
non-specific and include upper abdominal pain 
(78%), weight loss (67%), vomiting (48%), anorexia 
(45%) and weakness (42%) (70). These symptoms may
predate the diagnosis by 12-24 months but patients 
usually present within 12 months of their onset. 
Once suspected the diagnosis can normally be 
confirmed using either barium studies or endoscopy 
(71,72).
Gastric cancer in general, is an intra­
abdominal disease. The tumour typically spreads by 
local invasion of the stomach and surrounding 
structures. It metastasises to local and then 
regional lymph nodes and often spreads by the 
transcoelomic route to the peritoneum and omentum 
or occasionally to the ovaries giving rise to a 
Kruckenberg tumour. Haematogenous spread to the 
liver is via the portal vein. At laparotomy up to 
70% of patients will have evidence of tumour in 
the regional lymph nodes, 25% will have peritoneal 
involvement and a similar proportion will have
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liver metastases (70). There is direct 
infiltration of the pancreas in 23% and of the 
colon in 5%. The net effect of these findings is 
that relatively few patients have tumours which 
can be surgically cured despite the absence of 
metastases outwith the abdomen. Only 5-10% of 
patients will be alive 5 years after diagnosis and 
the majority of patients will die within the first 
2 years (73-76).
The pattern of recurrence at post mortem 
reflects the original mode of dissemination of the 
tumour, except that liver metastases are more 
frequent (54%) and that lung metastases can be 
detected in almost 25% of cases (76). The pattern 
of failure after successful surgical removal of 
the primary tumour was studied by Gunderson and 
Sosia (77). In this series, 107 patients were 
subjected to periodic re-operation. Eighty-six 
developed recurrent disease and of these 87% had 
local-regional recurrence which was defined as 
tumour in the gastric bed, lymph node recurrence 
or a localised peritoneal recurrence. Distant 
metastases were present in 30% of patients but 
were the sole site of recurrence in only 5%. These 
findings suggest some potential for the 
improvement of the local control, and this will 
be amplified in Chapter Two.
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While the rest of the World has made very- 
little progress in the treatment of gastric 
cancer, the Japanese have engineered a remarkable 
triumph. This triumph is, at least in part, 
related to the point at which the diagnosis is 
made in the natural history. Intuitively the 
diagnosis must be made earlier than in Europe and 
the USA, which is reflected in the higher 
proportion of early gastric cancer diagnosed in 
Japan. This ultimately translates into survival 
advantages for the patient; the 5 year survival 
for patients with gastric cancer in Japan is now 
50% (78). The earlier presentation in Japan can be 
explained by several factors. The Japanese 
screening programme undoubtedly leads to the 
detection of a significant proportion of early 
gastric cancer. However it may also serve to 
increase public awareness of gastric cancer and 
therefore encourage the Japanese individual to 
seek medical advice and investigation of dyspeptic 
symptoms earlier than his European counterpart.
However, there is some hope on the horizon 
for the UK. The study from Birmingham (79) and the 
report from Bristol (80) both suggest a higher 
proportion of early gastric cancer is now being 
diagnosed in this country, leading to a higher
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resection rate and in the long term hopefully 
improved survival.
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1.6 EARLY GASTRIC CANCER AND SCREENING FOR
GASTRIC CANCER
These 2 subjects are logically considered 
together because the main purpose of screening is 
to detect early gastric cancer, which can be 
readily cured by surgery.
Early gastric cancer is defined as tumour 
which has not penetrated the submucosa. Lesions 
may be protuberant, elevated, flat, depressed or 
excavated (81). Their average diameter is between 
2-3 cm (42) but lesions as large as 12.5 cm may 
occur (82). This has led some to suggest because 
these tumours can be slow growing (83), almost 
regardless of when the diagnosis is established, 
their natural history is such that they remain 
confined to the submucosa and are therefore easily 
cured by surgery (84). However, this seems 
unlikely because the Japanese have increased the 
proportion of cases with early gastric cancer from 
1% before 1951 (85) to over 40% in a population 
exposed to a screening programme with a 
concomitant improvement in overall survival (86).
In Japan over 4 million people are screened 
each year, with the detection of around 4000 new 
cases of gastric cancer (86). Indeed, it has 
become Japanese public health policy to make one
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screening investigation available to all adults 
over the age of 40 years once every 3 years. The 
screening method involves the use of a double­
contrast barium meal in conjunction with photo- 
fluorographic apparatus that takes 5-7 exposures 
per examination. The examination usually takes 
place in a mobile unit staffed by skilled 
technicians. Suspicious cases are referred for 
endoscopy. Although it seems likely that screening 
improves survival (86), in the absence of any 
randomised trial of screening versus no screening, 
it is not possible to unequivocally prove this 
assertion. At the present time case-control 
studies are used as an alternative to the 
randomised trial. In a recent case-control study 
from Nosetown in Osaka, the odds ratio of dying 
from gastric cancer in screened compared with 
unscreened individuals was 0.595 for males and 
0.382 for females thus supporting the notion that 
screening improves mortality rates (86).
In the United Kingdom it is now accepted 
that early gastric cancer is identical to the 
Japanese variety (87). In the 1960s the detection 
rate for early gastric cancer was as low as 0.7%
(88) although more recent data puts it at 10%
(89). In Bristol the number of early gastric 
cancers doubled during the two ten year periods of
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1965-75 and 1975-85. The survival rate of the 
patients with early gastric cancer was extremely 
good? 71% were alive at 5 years age (adjusted 
mortality 92%) (89).
However, although the screening programme 
has been successful in Japan the detection rate is 
low (1 in 1000 screened) and in the context of the 
lower rates of gastric cancer in the U.K. 
screening of all the population would be difficult 
to justify (90). Therefore an alternative has been 
to set up a clinic where only those patients with 
an exaggerated risk for the developement of 
gastric cancer are endoscoped (79). In Birmingham 
all patients, from 6 general practices, who were 
over the age of 40 years and complained of 
dyspepsia were referred to a dyspepsia clinic for 
endoscopy. Over a 2 year period 15 gastric cancers 
were diagnosed and 2 (15%) had early gastric
cancer (79). Sixty seven per cent of patients had 
a radical resection which is higher than the 18% 
reported previously from the same group (77). 
Nevertheless, it has been argued that even without 
a screening clinic the detection of early gastric 
cancer has increased (80) but our own data 
(Chapter Two) would not support this. The more 
frequent use of endoscopy in the latter part of 
the study was not associated with an improvement
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in survival. This favours the notion that 
endoscopy outwith the context of a screening 
clinic may not be sufficiently sensitive. 
Therefore screening at risk groups such as those 
over 40 years of age presenting with a history of 
peptic ulcer surgery would seem appropriate. As 
with Barrett's oesophagus, oncogene probes (57) 
could be used to examine endoscopic biopsies, 
particularly those taken from patients with a 
previous history of peptic ulcer surgery or those 
in whom the initial endoscopic screen shows 
dysplastic changes.
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1.7 SURGICAL TREATMENT AND STAGING
During the past 50 years there have been 
many reviews of the surgical treatment of gastric 
cancer which have produced remarkably similar 
findings. A summary of 8 studies (47,73-76,91-93) 
is shown in Table 1.3. Almost 80% of patients 
will have an operation. The remaining patients 
will be deemed unsuitable for surgery because of 
metastatic disease or because they are considered 
a poor operative risk. Approximately 60% of 
patients will have the tumour resected. In a some 
of the reviews it is not stated what proportion of 
these resections are considered curative, but 
usually this applies to 50% of cases. In any event 
the assessment of curative resection is very 
subjective and may not accurately reflect the 
adequacy of the surgery. Laparotomy and biopsy or 
a palliative bypass procedure is performed in 20% 
of cases. The results for surgery have remained 
remarkably static during the 30 past years. The 
only real area of improvement has been the 
reduction in the operative mortality rates. These 
have declined in one group's experience from 
22.5% in the period 1969-77 to 11.76% in the 
period 1978-82 (91). Gilbertson reviewed the
surgical experience in gastric cancer of the
47
No. of 
patients
7044
Table 1.3
Operation Resection 5 year 
rate rate survival
79 62 12
Results of surgery taken from 8 studies 
(1938-1982)
University of Minesota between 1936-1963. This 
consisted of 1983 cases (75). He concluded that 
more extensive surgical excisions had not led to 
an improvement in survival. Indeed, he argued that 
patients fared worse under an aggressive surgical 
policy; the 5-year survival of patients having a 
curative resection between 1950-58 was 28% 
compared to a 17% survival for 1958-63 when more 
radical surgery was performed. This finding was 
explained by an increase in operative mortality 
for partial gastrectomy (25.6%) and total 
gastrectomy (33.3%) during the second period. 
However, with the recent improvements in 
postoperative care this argument may now be 
spurious.
The Japanese experience with gastric cancer 
is considerable and the results which they have 
obtained with surgery are much better than has 
been achieved in the USA or Europe. In a review of 
4946 patients treated surgically in the National 
Cancer Centre, Tokyo between 1962-84 Maruyama (78) 
reported that in 4734 patients (95.4%) underwent 
tumour resection and that the 5 year survival for 
these patients was 51%. The postoperative 
mortality rate was only 1.6%. Admittedly over 50% 
of patients had tumours which had not penetrated 
the serosa but even so the results are impressive.
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What can be learned from the Japanese experience? 
The emphasis must be on early diagnosis and low 
postoperative mortality. The Japanese perform, by 
UK standards, radical surgery (94) but their 
results cannot be taken to indicate that a 
radical approach is necessarily best because there 
are no randomised trials in the Japanese 
literature which have addressed this issue. Indeed 
such studies are sadly lacking in the world 
literature and hopefully the MRC Surgical Gastric 
Cancer Trial may help resolve this problem.
A detailed technical account of the of the 
surgical approaches to gastric cancer is beyond 
the scope of this thesis and the reader is 
referred to a recent review by Cuschieri (95). The 
2 basic types of operation for gastric cancer are 
subtotal resection and total resection of the 
stsmach. Subtotal resection can be curative for 
antral tumours but for proximal tumours total 
resection is likely to be necessary. Both may be 
combined with an R1 lymph node resection (left and 
right cardiac nodes, nodes along the greater and 
lesser curvature) or an R2/3 resection (R1 plus 
gastric artery nodes,coeliac artery nodes, common 
hepatic artery nodes, lymph nodes of the splenic 
hilum,supra and infra pyloric nodes, splenic 
artery nodes, lymph nodes in the hepato-duodenal
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ligament, retro-pancreatic nodes, lymph nodes at 
the root of the mesentery, diaphragmatic and para- 
oesophageal nodes), splenectomy and for all except 
antral lesions the removal of the distal half of 
the pancreas. Clearly the operative mortality for 
the more extensive surgical procedures is higher 
and this must be carefully balanced against the 
improved outlook of survivors.
The staging of gastric cancer is extremely 
important because it allows valid comparisons of 
the results from different centres and different 
surgical approaches to this tumour . In 1984 a new 
staging system was devised to replace the 3 other 
systems in current use (UICC, The Japanese 
Research Society for Stomach Cancer (JRSSC) and 
The American Joint Committee on Cancer, for 
details see reference 95) and thus unify the 
description of gastric cancer in the USA, Europe 
and Japan. Essentially it is a TNM system which 
recognises 4 stages of gastric cancer (78) . Its 
application depends upon the surgeon following the 
guidelines of the JRSSC (94) coupled with a 
careful histological analysis of the resected 
tumour and regional lymph nodes. It is summarised 
in Table 1.4 and the corresponding survival 
figures from Maruyama (78) show that the new 
staging system effectively separates survival by
50
Stage
% surviving 
at 5 years
I la T1 NO 
lb T1 N1 
T2 NO
88
II T1 N2 
T2 N1 
T3 NO
65
III Ilia T2 N2 
T3 N1 
T4 NO
38
IV Any Ml 5
T - Primary Tumour
Tl:Tumour limited to the mucosa and submucosa 
T2:Tumour involves the subserosa 
T3:Tumour penetrates the serosa 
N - Regional Lymph Nodes
NO:No metastases to regional lymph nodes 
Nl:Involvement of perigastric lymph nodes 
within 3cm of the primary tumour 
N2:Involvement of regional lymph nodes more 
than 3cm from the primary tumour 
M - Distant Metastases
MO:No evidence of distant metastases 
Ml:Evidence of distant metastases
Table 1.4 The new TNM Classification with
survival according to Maruyama (78)
stage. However the detailed nature of the lymph 
node sampling must inevitably mean that this 
staging system is unlikely to gain wide acceptance 
for routine use in the UK but will nevertheless be 
crucial to the conduct of future clinical trials.
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1.8 CHEMOTHERAPY
During the past fifteen years there has been 
a sharp increase in the use of chemotherapy to 
treat disseminated gastric cancer. Initially the 
chemotherapy of gastric cancer consisted of single 
agent treatment, usually 5-FU. In the mid 1970s 
combination chemotherapy gained momentum as a 
sequel to the promising results obtained from the 
combination of 5-FU and the nitrosureas. There are 
now several different combinations of drugs in use 
which along with single agent data will be 
reviewed in this section.
1.8.1 Single Agent Chemotherapy
5-Fluorouracil (5-FU) has been the most 
widely used agent in gastric cancer and has an 
overall response rate of 22% with a response 
duration of between 4 to 5 months (96). The anti­
tumour effect of 5-FU has not been improved by 
giving the drug using a relatively intensive 
schedule of 15 mg/kg/24hr x 5 i.v., then 7.5
mg/kg on alternate days to toxicity (97), nor by 
administering the drug as a continuous infusion 
(30 mg/kg/24hr) for 72 hours every 2 weeks (98). 
However, this latter method is associated with
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virtually no systemic toxicity and may be worth
exploring in combination with other agents.
Otherwise, the most useful way of giving 5-FU is
2as an intravenous bolus at a dose of 750 mg/m 
every week.
Mitomycin-C is an antibiotic alkylating 
agent which was developed in Japan. It has
comparable activity to 5-FU, with a response rate
of 24% (99) but is more toxic. In particular, its 
use is associated with cumulative myelo-
suppression which most commonly manifests as 
thrombocytopaenia. Therefore the drug is now
usually given as an intravenous bolus every 6 
weeks. Another rather disconcerting finding is 
that mitomycin-C appears capable of inducing the 
haemolytic-uraemic syndrome. Fielding reported 
this condition in 8.5% of 251 patients receiving 
adjuvant mitomycin-C and 5-FU (100).
Adriamycin (doxorubicin) was investigated as 
a single agent for gastric cancer in the late
seventies and was found to have modest activity, 
ranging from 15-24% (101,102). It has subsequently 
been incorporated into many combination regimens 
but is not without toxicity. Alopecia is virtually 
universal following its use although this may be 
prevented in some patients by the use of scalp 
cooling. Cumulative cardiotoxicity also occurs at
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2doses above 550mg/m , but m  general this is not a 
practical clinical problem in patients receiving 
what is ostensibly palliative treatment. 
Epirubicin a derivative of adriamycin which is 
less cardiotoxic has similar activity to the 
parent compound and in general offers little 
advantage (103). Mitozantrone a bis-substituted 
anthraquinone that binds to DNA, showed no 
activity in a group of 32 patients with advanced 
gastric cancer (104). This is disappointing 
because, in general, mitozantrone shares the same 
spectrum of activity against tumours as adriamycin 
with the advantage of not producing alopecia.
The nitrosureas, carmustine (BCNU) and 
semustine (methyl-CCNU) have also been studied in 
gastric cancer. Methyl-CCNU has been used in 
combination with other cytotoxic drugs in a number 
of studies (102,105) and yet there is little 
evidence that it is an effective single agent. 
Moertel found only 8% of 37 patients responded 
(106). BCNU in limited testing had moderate 
activity (18%) in gastric cancer (107). The major 
drawback of the nitrosoureas is that they are 
emetogenic which presents a particular problem for 
patients with upper gastrointestinal malignancies. 
Other cytotoxic agents such as methotrexate have 
received remarkably little attention. A recent
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report from the Gastrointestinal Tumour Study 
Group (GTSG) suggests little activity for 
methotrexate in patients who had been treated with 
previous chemotherapy but did show promising 
results for another folate antagonist triazinate 
(108) .
Cisplatin has only recently been recognised 
to have important activity in gastric cancer (109- 
111), with response rates of 25% in studies which 
included patients previously treated with 
combination chemotherapy regimens. This is clearly 
encouraging and requires further investigation. 
Unfortunately, cisplatin is the most emetogenic of 
all the cytotoxic drugs in current use. 
Nevertheless, with modern antiemetics it shoud be 
possible to control the emesis and the most 
effective antiemetic for this purpose is high dose 
metoclopramide (see Chapter Three). Therefore the 
use of cisplatin should not be automaticaly 
excluded on the basis of vomiting.
Carboplatin, an analogue of cisplatin 
with less gastrointestinal and renal toxicity, has 
been tested in a small number of patients with 
gastric cancer but so far results are 
disappointing and suggest no significant activity
(112). We have evaluated the cisplatin analogue 
TNO-6 (cis-1,1 di(aminomethyl)-cyclohexane sulfate
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platinum II) in the treatment of gastric cancer
(113) and the results will be presented in Chapter 
Three.
1.8.2 Combination Chemotherapy
Following the identification of a few 
moderately active agents against gastric cancer 
the search for more effective combination 
chemotherapy regimens began. In particular, it was 
hoped that using drugs in combination would 
improve not only response rates but also the 
duration of response which, for single agent 
chemotherapy, was usually only a few months (96). 
Moertel (106) reported a randomised study of 5-FU 
and methyl-CCNU versus methyl-CCNU alone in which 
response to the combination was 40%. Moreover, 
patients survived significantly longer following 
treatment with 5-FU and methyl-CCNU than with 
methyl-CCNU alone. However, subsequent experience 
with this combination failed to confirm these 
results and response rates were equivalent to 
single agent 5-FU (101,114). Adriamycin has been 
added to the combination of 5-FU and methyl-CCNU 
(102,105,115). When the results of these studies 
are combined the response rate is only 35% (14 out 
of 40 patients with measureable disease). Levi et
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al (116) treated 35 evaluable patients with the 
combination of 5-FU adriamycin and BCNU (FAB) and 
found 18 (51%) of patients responded with a median 
duration of response of 10 months. However, a 
subsequent randomised study from this group showed 
no difference in the survival of patients treated 
with single agent adriamycin compared with FAB 
(117). Also Schnitzler et al (118) randomised 77 
patients to either FAB or 5-FU and BCNU in combi­
nation (FB) and reported that only 24% of patients 
responded to FAB and 11% responded to FB with no 
difference in survival between the 2 groups.
Because cisplatin has shown such promising 
activity as a single agent (109-111) it has been 
incorporated into a number of combination 
chemotherapy regimens. Wagener et al (119) treated 
2 0 patients with 5-FU, adriamycin and cisplatin. 
Nine (50%) of the 18 evaluable patients entered 
partial remission and 8 patients had stable 
disease. Similarly the combination of cisplatin, 
adriamycin and etoposide produced ojective tumour 
regression in 10 (62.5%) of 16 patient (120).
Unfortunatly success with cisplatin containing 
regimens has not been universal. A study from the 
USA (121) which investigated 5-FU, adriamycin and 
cisplatin revealed that only 10 (29%) of 35
patients responded and a further study in which
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cisplatin was combined with etoposide showed only 
1 of 33 patients responded (122).
Triazinate the anti-folate has been combined 
with mitomycin-C to treat advanced gastric cancer. 
Using this combination O'Connell et al (123) at 
the Mayo Clinic have treated 33 patients, 29 of 
whom had failed previous chemotherapy. Nine (27%) 
of patients had a partial response. This is a 
particularly interesting study because of the high 
proportion of heavily pre-treated patients who 
went on to respond to second line therapy.
The most widely used regimen in gastric 
cancer is the combination of 5-FU, adriamycin and 
mitomycin-C (FAM) (124). This regimen was 
developed on the basis that it utilised 3 of the 
most active drugs against gastric cancer. 
Preliminary results suggested that over 50% of 
patients would respond to the combination but 
subsequent experience has shown the figure to be 
nearer 40%. A detailed review of this regimen will 
be undertaken in Chapter Three.
Also in Chapter Three, we will review the 
results of the most promising new regimen from the 
1980s - 5-FU, high dose methotrexate and
adriamycin (FAMTX) (125). This is an interesting 
combination which exploits the synergism of 5-FU
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and methotrexate but unfortunately it appears to 
be particularly toxic.
1.8.3 Adjuvant Chemotherapy
Despite the relatively low activity of 
single and multiple chemotherapy regimens in 
advanced gastric cancer there have been a number 
of studies which have investigated the role of 
chemotherapy as an adjuvant to surgery.
As yet there is no convincing evidence that 
chemotherapy can improve the survival of patients 
after surgical resection of the primary tumour. In 
a large randomised series (616 patients), in the 
mid sixties, the Veterans Administration failed to 
show any benefit from intra-operative and adjuvant 
thiotepa - indeed the treatment group fared 
slightly worse (126,127). They also studied 
adjuvant floxuridine in 400 patients but again 
showed no difference in survival between control 
and treatment groups (128).
5-FU in combination with methyl-CCNU has 
been reported in 3 large series (129,130,131). The 
first of these from the GTSG showed significant 
benefit (40 deaths in 71 control patients; 29 
deaths in 71 treated patients) at a median follow 
time of 48 months (129) . However, in a similar
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study where 200 patients were randomised to 
intravenous 5-FU and oral methyl-CCNU for a period 
of 2 years, or no treatment after surgical 
resection, there was no significant difference in 
disease-free survival or overall survival between 
the 2 groups (13 0). Moreover, 2 patients in the 
treatment group developed non-lymphocytic 
leukaemia probably as a result of exposure to 
methyl-CCNU (132). The third study of 5-FU and 
methyl-CCNU whilst showing an early survival 
advantage for the treatment group, showed no 
difference in survival between treatment and 
control groups at a median follow up of 42 months 
(131).
The British Stomach Group has conducted a 
randomised trial of 5-FU and mitomycin-C against 
no treatment after surgery. They were unable to 
show any overall survival benefit from 
chemotherapy in this large well designed study 
which accrued over 400 patients (133).
More recently, FAM has been used as an 
adjuvant to surgery in a multicentre study (134). 
Three hundred and thirty patients have been 
randomised to FAM or a non-treatment control arm. 
The interim report presented at ASCO in 1986 
showed no significant difference in survival 
between the 2 groups and this trend continues (RC
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Coombes Personal Communication)
Not surprisingly there have been a number of 
adjuvant studies from Japan. However, because 
adjuvant chemotherapy is now established as a 
standard treatment following surgery in many 
centres in Japan, the most recent studies do not 
possess non-treatment control arms (135,136). This 
is disappointing because many of the earlier 
studies in the Japanese literature, taken to 
indicate definitive evidence of the value of 
adjuvant chemotherapy show only marginal benefits. 
Imanga and Nakazota reported benefit from adjuvant 
mitomycin-C (0.08 mg/kg x 2 weekly for 5 weeks 
after surgery) in a randomised study of 520 
patients with a 5 year survival of 68% in the 
treatment group compared to 54% in the control 
group (137). However these results could not be 
reproduced in a subsequent phase of the study 
where the same treatment formed one of 3 arms. The 
other 2 arms were mitomycin-C, 5-FU and cytosine 
arabinoside and a control am. Survival was not 
significantly improved with either chemotherapy 
(137). In a recent study from Japan the survival 
of 2873 patients was analysed after random 
allocation to one of 3 treatments (136). Group A 
were given bolus mitomycin-C with no further 
therapy. Group B were given bolus mitomycin-C and
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oral futraful for 1 year and group C were given 
oral futraful alone for 1 year. There was no 
difference in the 5 year survival of the 3 groups. 
Considering that a single dose of mitomycin-C is 
fairly close to a control arm these results 
suggest adjuvant treatment is not producing major 
improvement in the post operative management of 
gastric cancer.
At the present time there is no clear 
evidence that adjuvant chemotherapy is of value in 
gastric cancer. It is possible that only patients 
with a high risk of recurrent disease (such as 
those patients in whom the tumour has penetrated 
the serosa) should receive adjuvant chemotherapy 
in clinical trials, since this is the group most 
likely to benefit from this approach. Also, it is 
likely that more active cytotoxic drugs need to be 
identified in advanced disease before adjuvant 
treatment adopts an effective role.
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1.9 RADIOTHERAPY
There is relatively little information on 
the efficacy of radiation therapy in the treatment 
of gastric cancer. Many reviews (138,139) site the 
experience of Wieland and Hymmen who reported an 
11% three year survival and a 7% five year 
survival in 82 patients treated with radiation 
(60Gy) alone (140). These results published in 
1970 are taken to show that radiation therapy is 
effective in gastric cancer. They are' further 
supported by the findings of Hoshi who gave 
radiation preoperatively and reported histological 
evidence of radiation damage to the resected 
tumour in 25-88% of cases depending on the dose of 
radiation administered (141). However, Falkson and 
Falkson found no responders in a group of patients 
with measurable lesions treated with radiation 
alone, compared to a 17% response rate for 
patients treated with 5-FU and a 55% response rate 
for patients treated with a combination of 5-FU 
and radiation (142).
The promising results from the combination 
of radiation and 5-FU were also shown by a study 
from the Mayo Clinic in which patients with 
unresectable gastric cancer were randomly 
allocated to radiation therapy (35-40 Gy) and
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placebo or the same dose of radiation plus 5-FU 
given at a dose of 15 mg/kg daily over the 3 days 
prior to radiation (143). Forty eight patients 
entered the trial; the mean survival for the
combined treatment arm was 13 months and 3
patients were alive at 5 years compared to a mean
survival of 5.9 months for the radiation and
placebo arm and all patients in this group were 
dead at 5 years (143).
More intensive chemotherapy regimens have 
subsequently been used in combination with 
radiation therapy. One study randomised 90 
patients with locally unresectable gastric cancer 
to receive chemotherapy consisting of 5-FU and 
methyl-CCNU or radiation (50 Gy) given concurr­
ently with 5-FU and then later the same combi­
nation of 5 FU and methyl-CCNU (144). Although, 
there was a median survival advantage for the 
chemotherapy alone group (70 weeks versus 36 weeks 
for the combined modality group) the analysis at 5 
years favoured the combined modality treatment; 
16% of the combined treatment arm were alive 
compared to 7% in the chemotherapy arm (144). The 
reason for this was the early, higher mortality 
related to the combined modality therapy. In 
particular during the first 5 months of this 
treatment there were more deaths due to
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septicaemia in the combined modality arm.
A recent randomised study from the Eastern
Cooperative Oncology Group (145) failed to confirm
the Mayo Clinic data (143). Fifty seven patients
with histologically confirmed, unresectable
2gastric cancer were allocated to 5-FU 600mg/m
once weekly or radiation therapy (40 Gy) combined
2with 5-FU 600mg/m IV for the first 3 days of
2radiotherapy and then 5-FU 600mg/m IV weekly. The 
survival of both treatment groups was almost 
identical; for 5-FU alone the median survival was
9.3 months, 5-FU plus radiation 8.2 months. 
Toxicity was more marked with combined modality 
treatment (145).
The toxicity related to combined modality 
therapy was also highlighted in a study from 
O'Connell et al (146). In this pilot study 18 
patients with locally advanced gastric cancer 
were treated with 5-FU and adriamycin followed by 
concurrent radiation and 5-FU, and then 
maintenance therapy with 5-FU, adriamycin and 
methyl-CCNU. Patients experienced severe and 
prolonged nausea, weight loss and sepsis, and 
despite the achievement of local control of 
tumour all but 2 patients had progression of 
distant metastases.
Intra-operative radiation treatment has been
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pioneered by Abe et al (147,148). The radiation is 
delivered as a single fraction (30-40 Gy) to the 
tumour bed and surrounding lymph glands. In a non­
randomised trial (patients received intra­
operative radiation therapy depending on the day 
of surgery) there were survival advantages for the 
group treated with intra-operative radiation 
therapy. This advantage was particularly marked in 
those patients where the tumour had penetrated the 
serosa and invaded surrounding structures such as 
pancreas. For this group the 5 year survival was 
27% when treated with intra-operative radiation 
therapy compared to 0% when treated by surgery 
alone (147). These results have yet to be 
confirmed in a randomised trial.
There are few data on adjuvant radiation 
therapy in the treatment of gastric cancer. The 
British Stomach Group are currently evaluating 
this therapeutic approach and the results are 
awaited with interest (138).
Clearly, the precise role of radiation 
therapy in the management of gastric cancer has 
not yet been established. Combined modality 
treatment results in an escalation of toxicity 
with no proven survival advantage. Intra-operative 
radiation therapy is of interest but its efficacy 
remains to be confirmed in randomised trials.
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CHAPTER TWO
PROGNOSTIC FACTORS IN 
GASTRIC CANCER
2.1 INTRODUCTION
Although there have been a number of studies 
of the natural history and surgical treatment of 
gastric cancer from the U.S.A. and Europe, many 
use data derived from the 1930's and 1940's (73-
76) or use data compiled from several centres 
(70). There are relatively few contempory natural 
history studies (91) and we know of none from 
Scotland. Endoscopy became widely available in 
the 1970s and the effect that this technique may 
have had on the diagnosis and treatment of gastric 
cancer deserves investigation. This fact, coupled 
with the apparent gap in the literature of a 
natural history study from Scotland prompted this 
retrospective review. The present study describes 
the natural history of gastric cancer in a group 
of patients diagnosed consecutively in one centre 
in Glasgow (149).
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2.2 PATIENTS AND METHODS
We reviewed the clinical records of all 
patients with histologically proven gastric 
adenocarcinoma diagnosed in Glasgow Royal 
Infirmary (G.R.I.) between January 1st 1974 and 
December 31st 1984. We included patients with 
tumour of the cardia which had spread to involve 
the oesophagus. All patients were registered with 
the West of Scotland Cancer Surveillance unit 
which records the date of diagnosis, date of death 
and the cause of death in all cancer patients from 
this region. The following data were abstracted: 
duration and type of symptoms, details of 
operative procedure, pathology of the resected 
specimen, and details of any chemotherapy. The 
sites of recurrent disease were recorded. Local 
relapse was defined as tumour recurrence 
identified endoscopically or by barium studies or 
tumour recurrence within the gastric bed 
(identified at re-operation, post mortem, or by 
abdominal ultrasound or C.T. scan). Distant 
relapse was defined as tumour recurrence at all 
other sites including distant peritoneal spread 
and liver metastases.
Patients with advanced gastric cancer were 
defined as those in whom it was not possible to
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effect a surgical cure. Curative resections were 
defined as those in which there was no residual 
macroscopic disease after surgery.
Statistical Analysis
Data were analysed on the Glasgow University 
Computer (ICL 2976). Survival was analysed by the 
life table method. Using Cox's Regression Model 
(150), the effects on survival of the following 
independent variables were examined: duration of
symptoms before diagnosis, type of surgery, lymph 
node involvement, serosal involvement, resection 
margin involvement, site of primary tumour, 
presence of liver metastases and tumour histology.
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2.3 RESULTS
During the 11 year period 330 patients were 
diagnosed as having histologically confirmed 
gastric cancer in G.R.I.. Adequate clinical 
records and follow up were available for 328 
patients and the remaining 2 patients have 
therefore been excluded from analysis. The 
diagnosis was rare under the age of 45 years and 
the male to female ratio was 1.45:1 (Table 2.1). 
At presentation (Table 2.2), 30% of patients had 
an abdominal mass and 6% were jaundiced.
Surgical Procedures
All except 51 patients (15.5%) had some form 
of surgical treatment. The types of operation and 
survival of patients for each subgroup are shown 
in Table 2.3 and Figure 2.1. Almost all of the 
long term survivors came from the curative 
resection group, a group which survived 
significantly longer (p<0.001) than any other. 
Patients who had a palliative gastroenterostomy 
did not survive significantly longer than those 
having laparotomy alone, Celestin tube insertion 
or no surgery. The 11 years were arbitrarily 
divided into 2 periods. There was no change in the 
proportion of patients undergoing each surgical
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Age
(years)
Male
(NO.)
Female
(No.)
<45 10 5
45-54 32 5
55—64 50 33
65-74 71 54
>75 31 37
Total 194 134
Table 2.1 Characteristics of 328 patients with 
gastric cancer
Presenting symptoms
Anorexia and weight loss 
Dysphagia and vomiting 
Dyspepsia/abdominal pain 
Unexplained anaemia 
Emergency bleed/perforation
Number of 
patients (%)
272 (83)
210 (64)
211 (64)
92 (28)
55 (13)
Table 2.2 Presenting symptoms in 328 patients with 
gastric cancer
Percentage 
No. of surviving at years Median
Primary patients survival
treatment (%) 1 2 3 4 5 (montl
Curative resection 128 (39.0) 63 47 36 30 24 21
Palliative resection 32 (9.8) 27 14 3 3 0 6
Gastroenterostomy 33 (10.1) 8 0 0 0 0 4
Celestin tube 26 (7.9) 8 4 4 4 0 2
Laparotomy alone 58 (17.7) 9 0 0 0 0 2
No surgery 51 (15.5) 12 6 3 3 3 1
Table 2.3 Survival of patients with gastric cancer 
according surgical to procedure
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Figure 2.1 Survival by surgical procedure in 328 
patients with gastric cancer. (CR, 
curative resection:n=128; PR, palli­
ative resection:n=32; G, gastrectomy: 
n=33; C, celestin tube:n=2 6? L, lapa­
rotomy :n=58; NS, no surgery:n=51). 
Survival of CR versus PR: p<0.001.
Survival of PR versus G+L+NS: p<0.01
procedure during the 2 periods. In particular,the 
number of patients having curative resection 
remained the same (Table 2.4). However, operative 
mortality (death within 30 days of surgery) for 
the curative resection group changed from 17.6% 
between 1974-79 to 8.4% between 1980-84.
We have not analysed operative mortality for 
the other groups because it was often extremely 
difficult to differentiate between deaths due to 
operation and those due to progression of disease.
Survival of Curative Resection Group
Despite curative resection, only 24% of 
these patients were alive 5 years after diagnosis 
(Table 2.3). To define the prognostic factors for 
this group, we examined the effects of site of 
primary tumour, serosal margin involvement, re­
section margin involvement and lymph node 
involvement (as determined by histological examin­
ation of the resected specimen) on survival. The 
results are shown in Figure 2.2 and in Table 2.5. 
All patients with resection margin involvement 
relapsed and died. Otherwise, serosal involvement 
was the best predictor of survival (p=0.0004). 
Indeed, all but 5 patients with resection margin 
involvement had serosal involvement. Lymph node 
involvement was only a significant factor when the
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Operative
procedure
Curative resection 
Palliative resection 
Gastroenterostomy 
Celestin tube 
Laparotomy alone 
No surgery
Period
1974 - 1979
39.2 
10.8
8.5
8.5
22.3 
10.8
1980 - 1984
38.6 
9.0
11.6 
7.9
14.8
18.0
Table 2.4 Operative procedure by period
Percentage surviving 
at years:
No. of p
patients 1 2 3 4 5 value
Serosa 
Positive 90 
Negative 38
Margins 
Positive 33 
Negative 95
54 35 26 18 13 
85 78 59 59 47
41 7 7 0 0
69 58 43 36 28
0.0004
0.0005
Nodes 
Positive 65 
Negative 63
55 37 27 22 17 
71 57 45 37 31
0.04
Table 2.5 Survival by serosal involvement, 
resection margin involvement and lymph 
node involvement in 128 patients under­
going curative resection for gastric 
cancer
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Figure 2.2 Survival by serosal involvement (S), 
resection margin involvement (M) and 
lymph node involvement (N) in 128 
patients having a curative resection 
for gastric cancer
S M N Number
1 - - - 21
2 - - + 12
3 + - - 26
4 + - + 38
5 + + - 13
6 + + + 13
1+2 versus 3+4, p=0.02
3+4 versus 5+6, p<0.01
Percentage
survival
Lymph Resection
node margin Serosa No. 2 years 5 years
+ve -ve -ve 12 58 31
-ve -ve -ve 21 100 70
+ve -ve +ve 38 40 16
-ve -ve +ve 26 50 18
+ve +ve +ve 13 5 0
-ve +ve +ve 13 16 0
+ve +ve -ve 2 _ _
-ve +ve -ve 3 - -
Table 2.6 The effect of lymph node involvement on 
survival in 128 patients undergoing 
curative resection for gastric cancer
serosa and margins were not involved (Table 2.6). 
Survival related to the site of primary tumour is 
shown in Table 2.7. Survival was poorer (p<0.05) 
for patients with tumours of the cardia compared 
to the body or antrum. This was mainly because 
resection margin involvement was more frequent 
with tumours of the cardia (39.5%) than with 
tumours of the body (16.3%) or antrum (21.4%) 
(p=0.04). The degree of differentiation of the 
cancer had no significant influence on survival 
(Table 2.8), although patients with well differ­
entiated tumours had a better prognosis.
Endoscopy as a means of establishing the 
diagnosis had no effect on survival: the 102
patients undergoing endoscopy had a median 
survival of 663 days; the 26 patients who did not 
have endoscopy had a median survival of 570 days 
(p=0.22). Analysis of the duration of presenting 
symptoms revealed that patients with a long 
history (>6 months) survived longer than patients 
with a short history (<6 months) (Figure 2.3). 
This finding persisted even when an adjustment was 
made, using Cox's Regression model, for the 
prognostic factors described above (p<0.001).
Pattern of Recurrence
Seventy six percent of all patients having a
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Percentages
surviving at years
Site of No. of
primary tumour patients 1 2 3 4 5
Cardia 38 47 27 23 13 13
Body 43 68 54 45 35 28
Antrum 42 70 53 31 31 27
In 5 patients the site of primary tumour was not known
Table 2.7 Survival by the site of the primary 
tumour in 123 patients undergoing
curative resection for gastric cancer
Percentage 
surviving at years Median 
No of survival
Differentiation patients 1 2 3 4 5 (days)
Well 18 71 53 53 46 39 >1000}
Moderate 42 68 56 41 36 31 875}
Poor 68 59 41 28 20 15 544}
P
value
NS
Table 2.8 Survival by histology in 128 patients 
undergoing curative resection for 
gastric cancer
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Figure 2.3 Survival by duration of symptoms in 
121 patients having a curative 
resection for gastric cancer. 
A,<6months (n=88); B,>6months (n=3 3).
p<0.001
curative resection are dead. The sites of 
recurrent disease are shown in Table 2.9. Of the 
patients with resection margin involvement, 53.2% 
developed local relapse alone or in combination 
with distant relapse.
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Findings at
resection Site of relapse (per cent)
No of
Serosa Margins patients None Local Distant Both Unknown
+ve -ve 64 23.4 14.1 12.5 18.7 31.2
+ve +ve 26 11.5 23.1 7.7 30.1 26.9
Patients with no serosal involvement have been excluded
Table 2.9 Pattern of recurrence after curative 
resection for gastric cancer
2.4 DISCUSSION
The survival of this unselected series of 
patients was related to the type of surgical 
procedure performed. All long term survivors were 
derived from the group of patients in whom there 
was complete clearance of macroscopic disease at 
the time of resection. However, although 39% of 
all patients had such a 1 curative resection', only 
11% achieved long term survival. Serosal
involvement was the main determinant of survival. 
The group with serosal involvement had a 5 year 
survival rate of 13% compared to 47% for the group 
without. One explanation for the strong
correlation between serosal involvement and 
survival, is that they have free cells in the
peritoneal cavity, which is supported by the 
washings study (151). Indeed, I have also been 
able to demonstrate malignant cells in the 
peritoneum of a man with gastric cancer whose 
tumour had penetrated the serosa, but had not 
spread to lymph nodes (unpublished observations: 
St George's Hospital, London). Therefore it is 
possible that these patients have micrometastases 
at presentation.
Histological examination of the resected 
specimens showed that 24% of our curative
75
resection patients had tumour extending to the 
resection margin. The British Stomach Cancer Group 
reported a 22% incidence of resection margin 
involvement in their series of 390 patients (152), 
and Papachristou et al (153) found that following 
subtotal or total gastrectomy, 20% of their 350 
patients had tumour involving the resection 
margin. This problem may be overcome if the 
resection margins are examined by frozen section 
at the time of operation (153). The prognosis for 
patients with resection margin involvement is 
known to be extremely poor (152), and none of our 
31 patients in this category survived for more 
than 3 years. However, of our 31 patients, 84% 
also had serosal involvement which implies that 
their survival would have been limited, regardless 
of resection margin involvement. In Papachristou1s 
study only 23% of the 73 patients with resection 
margin involvement developed anastamotic 
recurrence. The majority of patients died of 
metastatic disease before such recurrence became 
manifest (153). It is possible, therefore that 
resection margin involvement like serosal 
involvement, is a marker of aggressive metastatic 
stomach cancer. Lymph node involvement is also 
regarded as a major survival determinant in 
gastric cancer (154). Our experience suggests that
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this is not the case and that spread of tumour to 
the lymph nodes only has prognostic significance 
in patients without serosal involvement.
In the curative resection group, patients 
with a long history of presenting symptoms had a 
better prognosis than those with a short history. 
This factor remained significant even when the 
data was subjected to multivariant analysis. This 
observation was first made in 1952 by Swynnerton 
and Truelove (73) and appears to apply to patients 
with early gastric cancer as well (88) . It is 
possible that the subgroup of tumours associated 
with a long history behave less aggressively and 
are therefore more amenable to surgical 
intervention. A recent study from Japan (155) has 
shown that long term survivors after gastrectomy 
for gastric cancer have a high frequency of the 
HLA-DR4 antigen when compared to normal healthy 
controls and other gastric cancer patients. Thus 
it will be important to examine the HLA antigens 
of patients with a long duration of presenting 
symptoms.
Another factor described as having 
prognostic significance after surgery is the 
presence of human epidermal growth factor (EGF) in 
the resected tumour (68). Results from a group in 
Hiroshima suggest that patients with tumours
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which possess EGF do considerably worse than those 
who do not. In this series of 158 patients with 
gastric cancer, EGF was detected using a 
combination of immunohistochemical and radio­
immunoassay techniques in 40% of tumours. The 
survival of these patients was significantly 
shorter after surgery. Of interest, is that in 52 
cases of early gastric cancer EGF could not be 
detected (68).
There is still debate about the best 
surgical approach to gastric cancer (156). In 
particular it remains controversial whether 
subtotal gastrectomy is as effective as total 
gastrectomy in affecting a cure (157,158). Pivotal 
to the argument is the consistently higher 
operative mortality of total gastrectomy (11.5- 
37.2%) compared to that of subtotal gastrectomy 
(3.2-23.7%) (157). Therefore although total
gastrectomy should theoretically provide more 
longterm survivors, this advantage is offset by 
the greater number of early operative deaths, 
especially in older patients. Randomised studies 
are require to resolve this controversy but from 
our experience, length of history of presenting 
symptoms should be part of the stratification of 
such studies. It would also be advisable to 
incorporate an assessment of the cytology of the
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peritoneal aspirates since this clearly has a 
major influence on survival (151).
The pattern of failure after resection for 
gastric cancer has been the subject of a number of 
reviews (77,158-160). In 2 post mortem studies 
loco-regional recurrence was found in 80% (158)
and 96% (159) of patients following subtotal
gastrectomy. However at post mortem almost 75-90% 
of patients also have distant metastases, these 
most commonly involving other abdominal organs 
(160). Our own data suggests that at least two 
thirds of patients have distant metastases at the 
time of relapse. Local recurrence alone was found 
in only 33% of patients but this is probably an 
overestimate, since it is likely that some of 
these patients have undetected metastatic disease.
As discussed in Chapter One, several 
classifications are used to describe the histology 
of gastric cancer (35,36,46). Most pathologists 
report at least the degree of differentiation of 
the tumour. Others divide gastric adenocarcinoma 
into the intestinal and diffuse types as described 
by Lauren (36), but as many as 30% of tumours may 
be unclassifiable or have a mixture of intestinal 
and diffuse forms (38). We were unable to 
undertake a retrospective review of the histology 
and classify it according to Lauren, therefore we
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have reported histology simply in terms of the 
degree of differentiation. The degree of 
differentiation did not significantly affect the 
survival of patients having a curative resection, 
but there was a trend in favour of a better 
prognosis for patients with well differentiated 
tumours.
We have not described the incidence of early 
gastric cancer in our patients. By inference it is 
likely that the incidence was low because the 
overall prognosis of the surgically resected 
group was so poor. Houghton et al (80) found that 
early gastric cancer now comprises 12% of all 
gastric cancers and attributed this increased 
incidence to the more routine use of endoscopy. 
However, in our series, endoscopy as a means of 
diagnosis had no impact on survival. One possible 
explanation is that to obtain maximum benefit from 
endoscopy this procedure must be linked to a more 
comprehensive programme for early detection (79).
As a palliative procedure, resection of the 
gastric primary, even in the presence of solitary 
or multiple liver metastases, improves survival 
(161,162), and more importantly may overcome some 
of the distressing symptoms which can develop. In 
our experience, palliative resection was 
associated with a longer survival (6 months) when
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compared to the survival of patients in the other 
advanced disease groups (1-4 months). However, 
patients who had a palliative bypass survived no 
longer than those who had a laparotomy alone or no 
surgical procedure. This of course does not 
necessarily mean that palliative bypass does not 
contribute to "quality of life" since measuring 
duration of survival ignores this factor, but it 
should mean that 'bypass' is not axiomatic for 
patients with irresectable tumour.
The prognosis for patients with gastric 
cancer remains very poor? the 5 year survival of 
the patients in this study was only 11%. Surgical 
intervention offers the only prospect of cure and 
is only likely to be successful in patients whose 
tumours have not penetrated the serosa. The best 
surgical approach is not established. Intra­
abdominal micrometastatic disease is a major 
problem even in patients having an apparently 
'curative' resection.
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CHAPTER THREE
CHEMOTHERAPY IN GASTRIC 
CANCER:
A CRITICAL APPRAISAL
82
3.1 TNO-6
3.1.1 Introduction
In pre-clinical studies TNO-6 was found to 
be less nephrotoxic in rodents than cisplatin but 
its activity against murine tumours was similar to 
that of cisplatin (163). A phase I study suggested 
that TNO-6 was less nephrotoxic in man and could 
be administered without hyperhydration (164). We 
thus initiated a study to evaluate the use of TNO- 
6 in patients with gastric adenocarcinoma. In 
addition because of the potential nephrotoxicity 
of this class of compounds, we decided to measure 
urinary N-acetyl-y glucosaminidase (NAG). NAG is 
a lysosomal enzyme which is found in plasma and a 
number of tissues throughout the body, including 
the kidney. Elevation of urinary NAG has been 
shown to be a sensitive marker of cis-platin 
induced renal tubular injury (165). Therefore, 
estimation of urinary NAG was used in this study 
as a means of monitoring possible TNO-6 related 
renal tubular damage.
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3.1.2 Patients and Methods
Patients
Sixteen patients (mean age 59 years, range
42-76) with histologically proven inoperable or
recurrent gastric cancer entered this study.
Thirteen were male and 3 female. Six had received
previous chemotherapy (5-FU, adriamycin and
mitomycin-C). Nine patients had liver metastases.
9Eligibility criteria were WBC >4x10 /l, platelet
9
count >100x10 /l, normal serum creatinine, 
performance status Eastern Cooperative Oncology 
Group (E.C.O.G) grading < 3 and at least three 
weeks since completion of previous chemotherapy (6 
weeks for mitomycin-C). Pretreatment evaluation 
included medical history, clinical examination, 
tumour measurement, serum urea and electrolytes, 
liver function tests, liver ultrasound, chest X- 
ray and full blood count.
Measurement of urinary NAG
Determination of NAG was based on the enzyme 
hydrolysis technique described by Lockwood and 
Bossmann (165). Using p-nitrophenyl-N-acetyl-B- 
D-glucosamide (Sigma Chemical Company Limited) as 
the substrate, NAG liberated p-nitrophenol which 
was measured spectrophotometrically. Samples of
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urine collected 24 and 48 hours before and after 
TNO-6 were centrifuged, then dialysed to remove 
low molecular weight enzyme inhibitors (166) 
before enzyme estimation.
NAG estimation was performed on the final 6 
patients entering the study. The urine collected 
for NAG measurement was also tested for protein, 
glucose and sediment.
Treatment protocol
2TNO-6 30mg/m was given by an intravenous
infusion in 50ml of 5% dextrose every 4 weeks in
the first 10 patients entering the study. The
remainder received TNO-6 with hyperhydration
consisting of 2 litres of dextrose given
intravenously over the 2 hours before and after
TNO-6 because the results of a phase I study which
became available during the course of this
investigation showed TNO-6 induced nephrotoxicity
when given as a short intravenous infusion (167).
If WBC<2.9x109/1 or platelets<75xl09/l treatment
9was delayed for 7 days or if WBC<1.0xl0 /I or
9
platelets<25xl0 /I therapy was stopped. If 
creatinine clearance decreased by 20% from the 
pretreatment values, therapy was terminated. 
Patients were reviewed weekly for the first 4 
weeks and every second week thereafter when
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clinical examination was performed and urea and 
electrolytes, liver function tests, full blood 
count and platelets were estimated. All patients 
received a minimum of 2 cycles of therapy, unless 
disease progression was observed or disease 
toxicity occurred. Treatment was continued in 
responding patients. All patients received routine 
antiemetic therapy.
Assessment of response
The response to treatment was determined 4 
weeks after chemotherapy. Death before this time 
was considered to reflect an inadequate trial of 
therapy. Duration of response and survival were 
taken from the initiation of chemotherapy. The 
definition of lesions used to assess response were 
as follows: measurable bidimensional - malignant 
disease measurable in 2 dimensions which included 
pulmonary, skin nodules and palpable primary 
tumours: measurable unidimensional - hepatomegaly. 
The liver was measured from below the costal 
margin in the midclavicular line and from the tip 
of the xiphoid process and the two values added 
together? evaluable, non-measurable - disease 
evident at endoscopy but not measurable.
Response criteria employed were those of the 
W.H.O. recommendations (168); complete response
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disappearance of all known disease for at least 4 
weeks; partial response - greater than 50% 
decrease (for bidimensional lesions or those
evaluable at endoscopy) or greater than 30%
decrease (for unidimensional lesion) in total 
tumour size for at least 4 weeks without
development of new lesions or progression of
unmeasurable lesions? stable disease - less than 
50% decrease or less than 25% increase in the size 
of measurable lesions or similar estimated changes 
in evaluable disease? progressive disease - 25% or 
more increase in the size of measurable lesions, 
estimated increase of 25% in evaluable disease or 
appearance of new lesions.
Assessment of toxicity
Toxicity of TNO-6 was assessed using W.H.O. 
recommendations (168).
3.1.3 Results
Response
The 16 patients with gastric adenocarcinoma 
were given 30 courses of chemotherapy. Five 
patients were not evaluable for response to TNO-6? 
3 due to early death, 1 because radiotherapy was 
given to the gastric primary to control bleeding
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and 1 patient in whom the only evidence of disease 
was an epigastric nodule which developed in the 
scar related to a previous gastric resection. The 
epigastric nodule was not biopsied and although it 
regressed on treatment with TNO-6 we do not think 
it should be regarded as an evaluable lesion since 
it may have been an inflammatory mass. Two of the 
early deaths occurred in patients who had received 
previous chemotherapy. Eleven patients were 
evaluated? 8 had progressive disease and 3 stable 
disease. The median survival for this group of 16 
patients was 10.5 weeks with a range of 1 - 56
weeks.
Toxicity
Gastrointestinal toxicity data was available 
on all patients but information related to other 
toxicities was not available for the 3 patients 
who died early or the one patient given 
radiotherapy.
Gastrointestinal
Despite prophylactic antiemetic therapy, all 
but 3 patients experienced some degree of nausea 
and vomiting. This was considered severe (W.H.O. 
grade 3) in 11, moderate (W.H.O. grade 2) in 1 and 
mild (W.H.O. grade 1) in 1.
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Renal
Renal function as determined by weekly serum 
creatinine and monthly creatinine clearance 
estimation, remained unchanged in 11 of 12 
evaluable patients. In the remaining patient the 
creatinine clearance dropped from a pretreatment 
value of 113 ml/min to 38 ml/min 3 weeks after a 
single pulse of TNO-6. Proteinuria did not occur 
but during this time the patient developed 
obstructive jaundice due to tumour in the porta- 
hepatis and had an episode of septicaemia. He died 
from progressive gastric cancer 5 weeks after the 
course of TNO-6. Post mortem permission was 
refused.
Estimation of urinary NAG
The 6 patients studied for enzyme excretion 
received hyperhydration with TNO-6. All had 
elevated pretreatment urinary NAG activity (normal 
0.43+/-0.14 units/mmol creatinine) with jaundiced 
patients having the highest values. Twenty four 
hours after TNO-6 the NAG enzyme activity showed 
increases over pretreatment values of 1.6 to 7.4 
fold (Figure 3.1). No significant changes with 
respect to serum creatinine and urine protein were 
observed in these patients following TNO-6.
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Figure 3.1 The effect of TNO-6 on urinary NAG in 
6 patients
White cell count Platelet count
x 109/1 x 109/1
Grade 0 2 8
Grade 1 5 1
Grade 2 3 0
Grade 3 2 2
Grade 4 0 1
Table 3.1 Haematological toxicity following TNO 
as assessed by WHO grading (22).
(Nadir counts on 12 patients)
Other manifestations of toxicity
The majority of patients developed evidence 
of myelosuppression though it tended to be mild 
(Table 3.1). Only 1 patient, who had previous 
chemotherapy with F.A.M., required platelet 
transfusion. No cases of fatal infection were 
observed. No changes were observed in serial 
transaminases, bilirubin and alkaline phosphatase 
other than in those patients with hepatic 
metastases who developed progressive disease. 
Alopecia was not observed in any of our patients.
3.1.4 Discussion
This study was terminated prematurely 
because TNO-6 induced nephrotoxicity was reported 
from other centres conducting concurrent Phase II 
studies in patients with other neoplasms (128). 
However TNO-6 had no apparent activity in gastric 
adenocarcinoma, which was particularly dis­
appointing, considering the activity of cis-platin 
in this tumour type. Four patients with gastric 
cancer were non evaluable, 3 due to early death, 2 
of whom had prior chemotherapy. The higher 
incidence of early death in the pretreated group 
reflects the poor prognosis of these patients and 
highlights the difficulties of attempting to
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identify new agents in gastric cancer, where 
currently most patients receive combination 
chemotherapy as part of their initial management.
Estimation of urinary N-acetyl-B- 
glucosaminidase is a sensitive method of detecting 
renal tubular damage (166). All patients, in whom 
NAG was measured, showed an increase following 
TNO-6, though none demonstrated concurrent 
alteration in serum creatinine or creatinine 
clearance, which reveals the insensitvity of these 
parameters in the early detection of the 
nephrotoxicity of cytotoxic agents. Although we 
found no definite TNO-6 induced alteration in 
renal function amongst our patients, other workers 
found significant elevation of serum creatinine in 
13% of 61 patients receiving TNO-6 for a variety 
of neoplasms, even when hyperhydration was 
routinely employed (169). In addition, when TNO-6 
is administered without hyperhydration it can 
produce renal failure and proteinuria (169). 
Consequently TNO-6 appears to offer no advantage 
over cisplatin in terms of nephrotoxicity and 
unlike cisplatin also produces glomerular damage. 
Emesis remained a difficult problem with TNO-6. It 
was similar to that encountered with cisplatin. 
Marrow suppression of a significant degree was 
recorded in 25% of patients, and in the absence of
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nephrotoxicity was the dose limiting factor.
In conclusion, the cisplatin analogue TNO-6 
produces nephrotoxicity that cannot be prevented 
by hyperhydration and has no significant activity 
in gastric cancer.
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3.2 5-FU, ADRIAMYCIN AND MITOMYCIN-C (FAM)
3.2.1.Introduction
In 1979 MacDonald published the first report 
on the use of the combination, 5-FU, adriamycin 
and mitomycin (FAM) in advanced gastric cancer 
(124). Eighteen (50%) of 36 patients had a partial 
response to this chemotherapy, and the treatment 
was considered relatively non-toxic. The update on 
this report confirmed the activity of FAM in 42% 
of 62 patients (170). The duration of response was 
also encouraging (median 9 months) and responding 
patients survived longer. Therefore in June 1980 
we initiated a phase II study of FAM in gastric 
cancer (171). The aim of the study was to assess 
the effectiveness of this regimen and to identify 
factors which might predict the response to 
therapy.
3.2.2 Patients and Methods
Eighty four patients with histologically 
proven advanced adenocarcinoma of stomach entered 
the study. None of the patients had received 
previous chemotherapy or radiotherapy. Three 
patients died from disease progression within 2
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weeks of commencing treatment and are not 
considered further. The characteristics of the 81 
evaluable patients are shown in Table 3.2 with 
performance status grading according to ECOG 
grading criteria. All patients in this study had 
disease which could be evaluated by one or more of 
the following means; clinical examination, 
radiology, hepatic ultrasonography, hepatic 
isotope scanning, abdominal computerised axial 
tomography or endoscopy. Formal evaluation of the 
response to therapy was made at the end of 2 
complete cycles (16 weeks) though the patients 
were also continually assessed at regular 
outpatient visits. WHO criteria of objective 
response to therapy were used (168) as outlined in 
Section 3.1.2.
The treatment schedule which was identical
to that used by MacDonald et al (170) consisted of 
2
5-FU 600mg/m (days 1,8,29 and 36); adriamycin
2 2 3 0mg/m (days 1 and 29) ; mitomycm-C lOmg/m (day
1). The cycle was repeated every 8 weeks. All
drugs were administered by bolus intravenous
injection into a peripheral vein using standard
precautionary techniques. Treatment was normally
given on an outpatient basis if the patient was
fully ambulant. Before each pulse of therapy the
peripheral blood was monitored and if the white
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Performance status n
0 5
1 27
2 33
3 14
4 2
Histology
Poorly differentiated adenocarcinoma 54
Moderately differentiated adenocarcinoma 14 
Well differentiated adenocarcinoma 10
Not available for review 3
Age: mean 54 years; range 33-77 years
Table 3.2 Characteristics of 81 evaluable patients 
with advanced gastric cancer
9
blood count was less than 3.5x10 /I or platelet
9
count less than 100x10 /I treatment was delayed 
for 7 days and thereafter modified as outlined in 
Table 3.3. Response to treatment was assessed 
after 2 cycles of chemotherapy. Patients 
demonstrating a complete response, partial 
response or stable disease received a further 2 
cycles of chemotherapy. Treatment was then stopped 
but was re-instituted in those deemed to have a 
complete response if they subsequently relapsed. 
Patients considered to have progressive disease at 
the end of 2 cycles were not given further 
chemotherapy. In addition, the development of 
progressive disease in patients receiving their 
third or fourth cycle of chemotherapy led to 
cessation of chemotherapy. Duration of response 
and survival were measured from the start of 
treatment.
Statistical analysis
Differences in performance status and age 
between the groups showing complete 
response,partial response, stable disease and 
progressive disease were examined using the (non- 
parametric) Kruskal-Wallis analysis of variance. 
The significance of differences between tumour 
histology, primary tumour resection and presence
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Drug dose WBC x 109/1 Platelets x 109/1
100^
50 '
0
> 3.5 
2.5 - 3.5 
< 2.5
> 100 
75 - 100 
< 75
Table 3.3 FAM treatment modification following 
marrow suppression in patients receiving 
chemotherapy for advanced gastric cancer
of hepatic metastases was calculated using Cox’s 
empirical logistic transform (172) after 
correcting for multiple comparisons. Survival was 
analysed as outlined by Peto et al (173,174) 
employing the Logrank test to calculate the 
significance of differences between survival 
curves. The effects of independant variables such 
as response to chemotherapy, sex, age, performance 
status and presence of hepatic metastases on 
survival were examined using Cox’s Regression 
Model (150)
3.2.3 Results
Response to treatment 
(Table 3.4)
A complete response was obtained in 4 
patients (5%), 1 of whom remains alive and disease 
free 5 years after commencing therapy (Patients' 
details see Table 3.5). In 24 patients (30%) a 
partial response was noted. Four patients with a 
partial response had successful resection of their 
primary tumour following chemotherapy. In 2 of 
these patients the tumour was originally deemed 
inoperable at laparotomy where a bypass procedure 
alone was performed. The other 2 patients did not 
have laparotomy prior to chemotherapy but were
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Complete Partial Stable Progressive p 
response response disease disease value
Patients n
Mean performance 
status 1.5
56Mean age
Median duration 
of response
(months) 10.5
Median survival 
(months) 17.1
Number with
hepatic metastases 3 
Histology
(3 patients not reviewed) 
Well differentiated 3
Moderately
differentiated 2
Poorly differentiated 23
Surgery
None 8
Laparotomy 6
Laparotomy +
bypass procedure 2
Resection 12
24
30
1.6
57
8
10
1.5
56
11
45
55
1.9
61
4.5
24
9
27
14
13
4
14
NS
NS
<0.001
<0.001
NS
NS
NS
NS
NS
NS
NS
Table 3.4 Details of 81 patients with advanced 
gastric cancer treated with FAM
Site of disease 
in patients 1-4
Assessment
of
response
Duration
of
response survival 
(months) (months)
Anastamosis 
of Polya gastre­
ctomy performed 
yrs earlier for 
gastric cancer
endoscopy 
CT scan of 
abdomen
58 and 
continuing
60
Resection margin 
after partial 
gastrectomy
endoscopy 
CT scan of 
abdomen
10
dead
3
L.supraclavicular clinical 11 12
adenopathy. chest x-ray dead
R.pleural effusion 
after partial gast­
rectomy for gastric 
cancer.No intra­
abdominal 
recurrence
4
Cervical/axillary clinical 29 30
lymphadenopathy endoscopy
with primary barium meal
gastric cancer
Response 
to FAM 
on
relapse
none
none
Table 3.5 Details of 4 patients showing complete 
response to FAM.
considered unsuitable for surgery as one had a 
massive primary tumour and the other had distant 
spread of disease in the form of bulky cervical 
lymphadenopathy. The overall duration of response 
was 10.5 months and the median survival of 
responders was 17.1 months. Response to 
chemotherapy usually occurred within the first 
cycle of therapy and was associated with 
stabilisation or improvement in performance status 
(PS) (mean PS before therapy 1.5; mean PS after 
therapy 1.3). Eight patients (10%) had stable 
disease with a median survival of 11 months.Forty- 
five patients (55%) had disease progression on 
therapy and all of these patients are now dead. 
The median survival for this group was 4.5 months. 
Mean age, performance status, tumour histology and 
incidence of primary tumour resection were similar 
in all groups. However, there was a highly 
significant difference (p<0.001) between the 
presence of hepatic metastases in the non­
responders and responders.
Survival of responders and non-responders 
are shown in the life table analysis graph (Figure 
3.2). Response to chemotherapy was associated with
a significant improvement in survival (Logrank
2test x =35.8 (1 d.f) p<0.001) . When the covanates 
sex, age, performance status and presence of
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Figure 3.2 Survival of 81 patients with advanced 
gastric cancer treated with FAM
WBC nadir X 109/1 n %
Grade* 0 4.0 25 42
Grade 1 3.0 - 3.4 14 23
Grade 2 2.0 - 2.9 10 17
Grade 3 1.0 - 1.9 8 13
Grade 4 1.0 3 5
9
Platelet nadir x 10 /I
Grade* 0 100 34 56
Grade 1 75 - 99 8 13
Grade 2 50 - 74 7 12
Grade 3 2 5 - 4 9 7 12
Grade 4 25 4 7
WHO grading (22)
Table 3.6 Myelosuppression in patients with 
advanced gastric cancer treated with FAM 
(60 patients with complete data 
available for analysis)
hepatic metastases were entered into Cox's 
Regression Model none reached the accepted level 
of statistical significance in explaining survival 
whereas response to therapy did (p<0.001).
Toxicity
Full data on the degree of myel©suppression 
were available in 60 patients. Approximately 50% 
of those developed some degree of myelosuppression 
though this was only considered significant in 20% 
(WHO grade 3 and 4 ) (see Table 3.6). Nausea and 
vomiting was encountered in 60% of patients and 
10% had prolonged gastro-intestinal side effects. 
One patient developed treatment related oral 
mucositis. Alopecia occurred in all patients 
completing two cycles of therapy. Scalp cooling 
was not used in any of these patients though they 
were all provided with a fashion wig, the colour 
and texture of which was matched to the patients 
own hair prior to commencing chemotherapy, in 
order to assure the best possible cosmetic result.
3.2.4 Discussion
This study is the largest single series of 
patients with advanced gastric cancer treated with 
FAM. The results confirm its activity in
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adenocarcinoma of the stomach and relative lack of 
myelotoxicity, though gastrointestinal side 
effects were more frequently observed than in 
MacDonald's original (124) and subsequent reports 
(170). Alopecia developed in all patients 
completing 2 cycles of therapy. Scalp cooling 
which may prevent the development of alopecia 
associated with adriamycin containing regimens, 
was not routinely available for our patients at 
the time of this study.
Though the overall response rate in our 
study of 35% was slightly less than the 42 to 44 % 
reported by other workers, the duration of 
response and survival of the responding group were 
similar (124,175,176). With the difficulties of 
accurately assessing response rate in gastric 
cancer the survival figures are a more accurate 
reflection of benefit from therapy. This is 
highlighted by the single agent therapy data, 
where response rates of between 15 to 25% rarely 
produced a significant improvement in survival 
(96).
However, as less than 50% of patients will 
respond and all are subject to some drug induced 
toxicity, attempts have been made to improve the 
selection of patients most likely to benefit from 
treatment. Analysis by Fraschini (176) and
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MacDonald (170) of their 47 and 62 patients 
respectively, treated with FAM, failed to show any 
statistical correlation between performance 
status, tumour histology, site of metastases, or 
resectability of the primary tumour on response to 
treatment. In a recent review of 137 patients the 
Gastrointestinal Tumour Study Group found 
performance status (p<0.01), presence of extra 
abdominal lymphadenopathy (p<0.05) and pulmonary 
metastases (p<0.05) to influence the response to 
treatment, though the fact that patients were 
treated with a variety of chemotherapeutic regimes 
makes overall interpretation more difficult (177). 
In our experience the presence of hepatic 
metastases was associated with a highly 
significant (p<0.001) negative effect on response 
to treatment. Indeed, the response rate in 
patients without hepatic metastases was 51%.
We recognise that patients showing a partial 
or complete response to chemotherapy may represent 
a pre-selected group in that their incidence of 
hepatic metastases was low. It is arguable that 
they constitute a group with a relatively 
favourable natural history regardless of any 
effect of chemotherapy. On the other hand, further 
analysis of our patients with progressive disease 
reveals that median survival did not differ
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significantly when patients without hepatic 
metastases (3 months) are compared to those with 
such metastases (5 months).
The application of this regime in clinical 
practice may seem limited in that more than half 
of the patients failed to show an objective 
response. This criticism should not detract from 
the frequent, and sometimes dramatic reduction in 
tumour mass that can accompany therapy with FAM, 
usually appearing during the first cycle of 
therapy and often associated with an improvement 
in performance status. Indeed, in one of our 
patients with tumour at the oesophagogastric 
junction, insertion of a Celestin tube was avoided 
following complete disappearance of dysphagia 
within 48 hours of administration of FAM.
Resection of gastric carcinoma following 
chemotherapy deserves comment. Although this 
applied to only 4 patients in the present study, 
they represent 25% of the group of 16 patients 
with unresected tumours who demonstrated a 
response to treatment. These 4 patients have 
survived 10, 20, 20 and 32 months respectively and 
2 are still alive. Since patients undergoing 
primary resection have a longer survival than 
those having bypass procedures (161), secondary 
resection may also contribute to an improvement in
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survival.
Of interest was a clinical curio which we 
have previously reported (178). One of the 
patients treated with FAM reported a dramatic 
improvement in his chronic obstructive airways 
disease following chemotherapy. This subjective 
improvement was confirmed by serial pulmonary 
function testing. It was mediated through an 
increase in FEV1 and vital capacity indicating a 
reduction in airway obstruction. The mechanism of 
action of chemotherapy in this particular clinical 
situation is not clear. One possible explanation 
is that the chemotherapy sensitised the bronchi to 
the oral salbutamol which was continued throughout 
his chemotherapy. This has been proposed as one of 
the modes of action of steroids in asthma 
(179,180).Chronic obstructive airways disease need 
not be a contraindication to chemotherapy.
Chemotherapy with FAM offers, acceptable 
outpatient palliative therapy in 35% of all 
patients with advanced gastric cancer? the 
response rate was greater in those without hepatic 
metastases. In a small proportion of patients 
with inoperable tumours treatment with FAM 
rendered these tumours operable and these patients 
seemed to fare particularly well after 
chemotherapy. Nausea and vomiting remained a
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significant problem and our efforts to deal with 
this are outlined in section 3.5.
3.2.5 My Involvement in the FAM Study
Although this data was generated from 4 
centres in Scotland the majority of patients 
(n=53) were from Glasgow Royal Infirmary and I was 
personally involved in the management (including 
assessment of response and toxicity) of all of 
these patients.
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3.3 5-FU,METHOTREXATE AND ADRIAMYCIN
3.3.1 Introduction
Bertino and his colleagues were the first to 
demonstrate a synergism between 5-FU and 
methotrexate (181). They showed enhanced cytotoxic 
activity in a variety of tumour models when 
methotrexate was givan sequentially to 5-FU. Klein 
utilised this effect in the treatment of gastric 
cancer and reported a very high response (60%) in 
30 patients treated with the combination of 5-FU, 
methotrexate and adriamycin (FAMTX) and emphasised 
the lack of toxicity (125). Other data from a 
small pilot study of adriamycin and methotrexate 
partly corroborated Klein's results by showing an 
objective response in 10 of 14 evaluable patients 
treated with this 2 drug combination (182).
Therefore we considered it appropriate to 
test FAMTX in our centre (183) given the 
apparent efficacy and low toxicity of this 
regimen.
3.3.2 Patients and Methods
Twelve patients comprising 7 males and 5 
females with a mean age 61 years (range 41 - 78)
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entered the study. One patient had received
previous chemotherapy. All had measurable disease
and only 1 patient had overt hepatic metastases.
Performance status (ECOG grading) was I in 11
patients and II in 1. All patients had normal
haematological indices prior to chemotherapy, a
normal serum creatinine and a creatinine clearance
>50 ml/min. Two patients had elevation of the
serum bilirubin at 175 umol/1 and 63 umol/1
respectively,but the remaining patients had normal
liver function. The regimen consisted of: Day 1
2
methotrexate 1.5 g/m IV bolus followed 1 hour
2
later by 5-FU 1.5g/m IV bolus and 24 hours later
2by folinic acid 50 mg/m IV six hourly, combined
with forced alkaline diuresis and continued until
serum methotrexate levels were outwith the toxic
2range; Day 14 adriamycin 3 0mg/m IV, cycled every 
28 days. Response to treatment and toxicity were 
assessed according to WHO criteria (168).
3.3.3 Results
The 12 patients received 35 courses of 
treatment. Following chemotherapy 2 patients had a 
partial response, 2 patients had stable disease, 7 
patients had disease progression and 1 patient was 
not evaluable due to death from septicaemia. The
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major toxicity was myelosuppression with a white
9cell count nadir <1x10 /I m  4 patients and 1-
9 .2x10 /I in 4 patients. The 2 patients with
abnormal liver function had nadir white cell
9 . . .counts of >3x10 /l. The median time of the white
cell count nadir was day 13. Three patients 
developed life threatening septicaemia during the 
neutropenic phase and 1 further patient died of 
gram-negative septicaemia. Thrombocytopaenia was
observed in only 1 patient, with a nadir count of
9 . .54x10 /l. Mucositis was recorded m  3 patients and
an erythematous skin rash in 2. Although all 
patients were given routine antiemetic treatment, 
4 still experienced nausea and vomiting. There was 
no nephrotoxicity.
3.3.4 Discussion
Clearly it was premature to report the 
activity of this regimen in gastric cancer since 
the confidence intervals on the response rate 
(16%) in such a small patient sample are wide (0 - 
38%). However, the toxicity of the regimen 
deserves comment. In particular, we were alarmed 
by the high incidence of life threatening 
infection, occurring in the context of 
neutropenia, which had not been anticipated on the
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basis of Klein's original report (125). The agents 
mainly responsible for the myelosuppression appear 
to have been methotrexate and 5-FU, which was 
reflected in the occurrence of the white cell 
count nadir on day 13 of the treatment cycle. In 
terms of myelosuppression adriamycin was less 
important, and it was of interest that the 
patients with abnormal liver function did not 
develop significant neutropenia. The reason for 
the more severe myelosuppression in our study when 
compared to Klein's experience (125) is not clear, 
but it certainly cannot be attributed to the use 
of inadequate 'folinic acid rescue'. Subsequent to 
our study, the EORTC also reported (184) that they 
were unable to reproduce the high response rate 
described by Klein. They treated 71 patients in a 
multicentre trial with only 22 (33%) responding
patients and 4 toxic deaths (184). Therefore the 
toxicity and as yet unconfirmed efficacy indicates 
that this regimen should not be routinely used and 
that its inclusion in adjuvant protocols is 
potentially hazardous.
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3.4 THE IMPACT OF CHEMOTHERAPY ON THE OVERALL
SURVIVAL OF PATIENTS WITH ADVANCED DISEASE
3.4.1 Introduction
Although it is clear that patients with 
gastric cancer who respond to chemotherapy live 
longer (170,171), there is little evidence that 
chemotherapy improves overall survival rates. 
Indeed, in a recent randomised study from the 
North Central Cancer Treatment Group (185) in 
which 151 patients were allocated to 1 of 3 
treatment regimens; single agent 5-FU, 5-FU and 
adriamycin, or FAM there was no survival advantage 
for any treatment arm. These findings are 
disconcerting and indicate quite clearly that 
there is a need for further randomised trials of 
combination chemotherapy versus no treatment in 
gastric cancer. At the present time there is only 
one small study in the literature which randomised 
37 patients to either no treatment or a 5 drug 
combination of vincristine, methotrexate, cyclo­
phosphamide, 5-FU and mitomycin-C. It showed 
almost identical median survival times for treated 
and control groups of 9.5 and 9 weeks respectively 
(186).
The retrospective review outlined in Chapter
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Two allowed investigation of the contribution of 
chemotherapy to overall survival. During the last 
5 years of the study a medical oncology unit was 
established in the centre and a larger proportion 
of patients with advanced disease received 
chemotherapy. This permitted comparison of the 
survival of patients with advanced disease during 
2 periods, one when chemotherapy was rarely given 
and the other when chemotherapy was frequently 
given.
3.4.2 Patients and Methods
Two hundred and two patients in the 
retrospective review had advanced disease at 
presentation (this includes 2 patients who had 
curative resections subsequent to chemotherapy). 
Patients with advanced disease were defined as 
those in whom it was not possible to effect a 
surgical cure. Of these 202 patients, 50 were 
given chemotherapy. Forty five received FAM, 3 
received TNO-6 and 2 received 5-FU alone. Using 
Cox's regression model (150) the effect of 
chemotherapy on survival was analysed taking into 
account the independant variables of type of 
surgery performed on each patient, tumour 
histology and presence of liver metastases.
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All patients Excluding deaths 
within 14 days
median % median %
survival surviving survival surviving
(days) 1 year (days) 1 year
No chemotherapy 
(n=152) 
Chemotherapy 
(n=50) 160
71
24
9
155
108 12
23
All patients chemotherapy versus no chemotherapy p<0.001) 
Exclude early deaths chemotherapy versus no chemotherapy p=0.02
Table 3.7 The effect of chemotherapy on the
survival of patients with advanced
disease.
3.4.3 Results
The 50 patients who received chemotherapy 
survived significantly longer (p<0.001) than those 
who did not (Table 3.7). To correct for patient
selection for chemotherapy all deaths within 14 
days of diagnosis were excluded. The signi­
ficance value changed to p=0.02 once these deaths
had been excluded (Table 3.7). In a further effort
to elucidate the effect of chemotherapy on 
survival we compared the survival of patients with 
advanced disease from the period 1974 - 1979 (when 
8% of patients received chemotherapy) with the 
survival of patients from the period 1980 - 1984
(when 45% of patients received chemotherapy). We 
found no significant difference (p=0.4) in 
survival rates, suggesting that chemotherapy did 
not influence prognosis.
3.4.4 Discussion
Treatment of gastric cancer with single
agent chemotherapy results in tumour regression in 
approximately 10-20% of patients. This regression 
is normally short lived and of little biological 
significance to the patient (96). With the 
introduction of combination chemotherapy regimens
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such as FAM, response rates in the region of 35- 
40% were reported (170,171) and it was observed 
that these responses could persist for longer (10 
months) and that responding patients survived for 
a median of 17 months. Untreated, advanced gastric 
cancer has a very poor prognosis. A median 
survival of 4 months was reported in one North 
American series (187). Therefore it was considered 
possible that combination chemotherapy was 
prolonging overall survival. As a result, there 
have been few randomised trials comparing the 
survival of patients treated with combination 
chemotherapy, against a non-treatment control 
group.
In the absence of all but one controlled 
trial (186) this retrospective analysis provided 
valuable information on the effect of chemotherapy 
on overall survival. In the second period of the 
study, 45% of patients received chemotherapy 
compared to 8% of patients who received 
chemotherapy during the first period. In other 
respects the two patient populations were very 
similar. In particular, there was no major change 
in the type or proportions of surgical procedure 
performed, both groups were matched for the 
presence of liver metastases, the patients were 
drawn from a consecutive series, thus eliminating
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the bias normally created by patient selection 
for a retrospective study, and information was 
available on virtually all patients for follow up. 
Using multivariate analysis, patients with 
advanced disease who received chemotherapy 
survived significantly longer than those who did 
not. However, when all deaths within 14 days of 
diagnosis were excluded from analysis, the 
difference was less marked, although still 
significant (p=0.02). The rationale for excluding 
early deaths was based on the assumption that 
patients selected for chemotherapy are usually 
more fit than those who are not, and that such 
patients are normally anticipated to live more 
than 14 days. The next step in the analysis was to 
compare the survival of patients with advanced 
disease during the 2 periods, one when 
chemotherapy was rarely given and the other when 
almost half of the patiens were given 
chemotherapy. The survival of these 2 groups of 
patients was identical.
Why should a treatment which can produce 
tumour regression in 35-40% of patients fail to 
make an impact on overall survival? Chemotherapy 
is not devoid of side effects and may well 
contribute to an increased morbidity and mortality 
in patients who do not respond. Certainly this is
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true of more toxic regimens (183,188), and this 
effect may outweigh the beneficial effects of 
chemotherapy in some patients. Thus, in order to 
optimise the use of chemotherapy, the 
administration of chemotherapy must be closely 
monitored so that toxicity is minimised. Side 
effects related to the gastrointestinal tract can 
be controlled by the appropriate antiemetic 
(section 3.5) and the timely use of antibiotics 
may prevent septicaemic episodes.
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3.5 THE CONTROL OF NAUSEA AND VOMITING INDUCED BY
CYTOTOXIC DRUGS
3.5.1 Introduction
Chemotherapy used in the treatment of 
gastric cancer is palliative. Therefore, 
optimisation of the use of chemotherapy depends on 
the selection of patients most likely to respond 
(such as those without liver metastases) and the 
minimisation of side effects. The most important 
side effects from the patients1 point of view are 
nausea and vomiting, followed by alopecia (189). 
Alopecia may be prevented in some cases by the 
judicious use of scalp cooling (190). However, for 
patients with upper gastrointestinal malignancy 
nausea and vomiting is a particularly distressing 
symptom because it is often part of the symptom 
complex related to the tumour. Furthermore, these 
symptoms may excacerbate the anorexia commonly 
associated with gastric cancer and lead to more 
weight loss and general malaise. In view of this, 
as part of the strategy for the treatment of 
gastric cancer the development of effective 
antiemetic regimens was considered a priority. It 
was clear that if good control of emesis could be 
achieved, for any given patient, the balance would
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shift in favour of active treatment.
There is a large number of antiemetics 
available but none is completely effective or 
devoid of side effects (191). We have therefore 
performed a number randomised, comparative trials 
in an effort to assemble the best antiemetic 
"package". Cisplatin is the most emetogenic of the 
cytotoxic drugs used to treat cancer and is by 
convention considered separate to other cytotoxic 
drugs in antiemetic trials. The nausea and 
vomiting associated with the administration of 
cisplatin has understandably deterred many 
clinicians from using this drug to treat gastric 
cancer. This therapeutic drawback is underlined by 
the data from Chapter Two which indicated that 
cisplatin is one of the most useful drugs in the 
treatment of gastric cancer.
The following data will relate to 4 
randomised trials (2 of which included 
chemotherapy regimens containing cisplatin) and an 
open trial where the potential of a new antiemetic 
compound, a 5-hydroxytryptamine receptor (5-HT3) 
antagonist, was tested (192-196).
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3.5.2 Patients and Methods
Randomised trials
Patients with a variety of malignancies, 
receiving chemotherapy for the first time entered 
these trials.
Trial 1
Patients were randomly assigned by a double 
blind, double dummy crossover technique to one of 
the following antiemetics: metoclopramide given as 
a 50mg loading dose intravenously 30 minutes 
before chemotherapy, followed by a 12 hour 
intravenous infusion of 5mg/kg in 500ml 
physiological saline or chlorpromazine 25mg (1ml) 
given intramuscularly every 4 hours for 12 hours, 
beginning with the chemotherapy.
Trial 2
Patients were randomly assigned using a 
double blind crossover method to nabilone 2xlmg 
capsules combined with prochlorperazine (5mg) or 
nabilone 2xlmg and placebo. The first dose was 
given at 10pm the night before chemotherapy, and 3 
further doses were given at intervals of 12 hours, 
although if vomiting did not occur the final dose 
was omitted.
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Trial 3
This was a randomised open crossover trial 
where patients were assigned to nabilone and 
prochlorperazine or metoclopramide and 
dexamethasone and crossed on the second course. 
Nabilone was given as in trial 2. Metoclopramide 
was given as a 2mg/kg loading dose in 250ml of 
physiological saline administered as an IV 
infusion over 15 minutes before chemotherapy 
followed by an IV infusion of 3mg/kg in 500ml 
physiological saline over 8 hours. Just prior to 
chemotherapy dexamethasone 20mg made up to a 10ml 
volume with physiological saline was administered 
IV over 3 to 5 minutes. (More rapid injection can 
lead to an unpleasant paraesthesia).
Trial 4
Patients were randomly assigned using a 
single blind technique to one of 3 antiemetics. 
Domperidone 20mg tds or metoclopramide 20mg tds 
given orally on the day before chemotherapy and 
continued for 3 days with 20mg bd on day 4 and 
20mg on day 5 after chemotherapy or dexamethasone 
given 4 mg tds on the day before chemotherapy and 
continued for 3 days, with 4mg bd on day 4 and 4mg 
od on day 5. On the day of chemotherapy the second 
dose of metoclopramide or dexamethasone was given
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as an IV bolus (domperidone was not available for 
IV administration). If the first antiemetic 
regimen failed to control nausea and vomiting 
patients were randomly allocated to 1 of the 
remaining regimens for the next course of 
chemotherapy, and if that failed they were 
allocated to the third regimen. The chemotherapy 
was stratified into regimens of high (those 
containing intravenous doxorubicin, epirubicin or 
cyclophosphamide; there were 14 patients in each 
antiemetic group) and low emetogenic potential
Assessment of antiemetic efficacy and side effects 
For trials 1-3 the number of episodes of 
ernesis, duration of vomiting, severity and 
duration of nausea and any change in appetite were 
recorded for 24 hours following administration of 
chemotherapy, on an in-patient basis. Side effects 
of treatment including sedation, dizziness, 
dryness of mouth, dysphoria and extrapyramidal 
reactions were recorded, and graded none, mild, 
moderate or severe. All recordings were made by 
senior nursing staff or medical staff. After each 
antiemetic course the patient indicated the extent 
of emesis control by marking a cross on a 10cm 
linear analogue scale ranging from 'not at all 
sick* to 'very sick'. After the second antiemetic
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course the patient completed a questionnaire to 
determine preference (if any) for either 
antiemetic regimen and outline reasons for this 
preference. For trial 4 nausea, vomiting and side 
effects were assessed on an in-patient basis for 
24 hours after chemotherapy and the patients 
completed a daily diary of these symptoms for at 
least the following 5 days, or until the symptoms 
resolved.
Non-randomised trial
Patients with nausea and vomiting refractory
to standard antiemetic therapy were selected for
treatment with the 5-HT3 antagonist GR38032F.
Immediately before chemotherapy a dose of 4mg 
(base equivalent) of GR38032F (Glaxo group 
Research) was given by intravenous injection over
5 minutes and a further 4 mg orally was given at 
the same time. Ths oral dose was repeated 5 and 10 
hours after chemotherapy. Nausea, vomiting and 
side effects were recorded on an in-patient basis 
for the 24 hours after chemotherapy.
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3.5.3 Results
Randomised trials 
Trial 1
Ninety five patients (52 women, 43 men; mean 
age 49) received chemotherapy regimens consisting 
of cisplatin or cisplatin analogues in 43 and 
regimens without cisplatin in 52. Ten patients
given cisplatin and 11 of the others did not 
complete 2 courses because of death (10),
violation of the protocol (7), stopping 
chemotherapy (2), refusal of intramuscular
injections (1) and a dystonic reaction (1).For 
patients receiving cisplatin regimens there was 
complete control of nausea and vomiting in 13% 
when treated with chlorpromazine and 19% when 
treated with metoclopramide. For the regimens
without cisplatin there was complete control of 
nausea and vomiting in 42% of patients treated 
with chlorpromazine and 46% with metoclopramide. 
Among patients who completed the crossover there 
were no significant differences in vomiting, 
nausea or appetite, except that among patients 
given regimens containing cisplatin the severity 
of nausea was significantly less in those who 
received high dose metoclopramide (p<0.01) and a 
significant number of these patients preferred
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high dose metoclopramide (22 v 5, p<0.01); 6 had
no preference. The assessment on the linear 
analogue scale in this chemotherapy group also 
favoured high dose metoclopramide (p<0.01). No 
preference was shown in the group given regimens 
not containing cisplatin. In both chemotherapy 
groups there was no significant relation between 
the order of administration of active drug and 
drug preference (Fisher's exact test). Adverse 
effects except extrapyramidal reactions were 
similar for both antiemetics.
Trial 2
Thirty four patients (20 women, 14 men? mean 
age 55 (range 39-76)) entered the study. All were 
receiving chemotherapy regimens without cisplatin. 
Four patients did not complete 2 courses: 3 died
and chemotherapy was stopped in 1.There was 
complete control of nausea and vomiting in 85% of 
patients given nabilone and prochlorperazine and 
74% of patients given nabilone. Among the patients 
who completed the crossover there were no 
significant differences in nausea, vomiting, 
appetite, assessment on the linear analogue scale 
or adverse effects other than those on the central 
nervous system (euphoria, dysphoria or 
disorientation) which were significantly less
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common with the combination of nabilone and 
prochlorperazine (p<0.01).Other side effects such 
as sedation (80%),dizziness (60%) and dry mouth 
(80%) occurred with similar frequency in both 
groups. A significant number of patients preferred 
the combination (15 v 1, p<0.001); 14 had no
preference) mainly because it was assosciated with 
less CNS side effects. There was no significant 
relation between the order of administration of 
the drug and drug preference (Fisher's exact text).
Trial 3
Eighty patients (47 women, 33 men? mean age 
42 (range 18-68)) entered the study. All patients
were receiving cisplatin in a dose range of 20-
250mg/m or the cisplatin analogues carboplatm or 
JM9. Ten patients failed to crossover because of 
change of chemotherapy in 5, protocol violation in 
4 and extrapyramidal reaction in 1. There was 
complete control of nausea and vomiting in 24 
patients (32%) given metoclopramide and 
dexamethasone and 14 patients (19%) of patients 
given nabilone and prochlorperazine. This 
difference was not significant but the scores for 
emesis on the linear analogue scale were 
significantly better for metoclopramide and 
dexamethasone (2.2+/-.32) compared to nabilone and
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prochlorperazine (3.5+/-0.37),p=0.018. With regard 
to side effects the following were significantly 
more frequent with nabilone and prochlorperazine; 
dizziness (p<0.001), sedation (p<0.01), dryness of 
the mouth (p<0.001) and dysphoria (p<0.05). 
Extrapyramidal reactions were only seen with the 
metoclopramide and dexamethasone combination.
There was no significant patient preference 
for either antiemetic (31 v 26; 13 no preference). 
However for patients given carboplatin, a 
significant proportion preferred nabilone and 
prochlorperazine (p=0.013). This was mainly 
because patients preferred the antiemetic given by 
the oral route. There was no significant relation 
between the order of administration of antiemetic 
and antiemetic preference.
Trial 4
Twelve of 20 (60%) of patients randomised to 
receive dexamethasone had no nausea or vomiting. 
This was significantly better than metoclopramide 
where control of nausea and vomiting was seen in 
only 5 of 20 (25%) patients (p=0.005). With
domperidone, 8 of 20 (40%) patients experienced no 
nausea and vomiting, which was not significantly 
better than metoclopramide or significantly worse 
than dexamethasone.
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Of the 35 patients who failed first line 
therapy, 12 received a second option. Of these, 6 
received dexamethasone and only 1 experienced 
nausea and vomiting. The remaining 6 either 
received domperidone (n=3), or metoclopramide 
(n=3) but all experienced nausea and vomiting. No 
patient was given metoclopramide or domperidone as 
a third line antiemetic. Dyspepsia was similar 
with all 3 antiemetics (39-52%) and was in general 
extremely mild. The median duration (range) in 
days of the symptoms were as follows: nausea 3.5
(1-14); vomiting 2 (1-13); retching 2 (1-14); time 
for appetite to become normal and general activity 
to return to normal 3 (2-10) and 3.5 (2-14)
respectively.
Non-randomised trial
Thirteen women and 2 men (mean age 57) took 
part in this open study. In 13 patients the 
chemotherapy regimen was unchanged from that which 
had caused nausea and vomiting previously and in 2 
patients there was a minor modification of 
chemotherapy. The details of previous antiemetic 
therapy and chemotherapy regimens are shown in 
Table 3.8. No patient was given cisplatin. The 15 
patients received 31 courses of GR38032F. Only 1 
patient experienced nausea and vomiting. In a
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Antiemetic (and dose x 4 daily)
No of 
patients
Domperidone 2Omg+dexamethasone 4mg 6
Domperidone 20mg only 5
Dexamethasone 4mg only 2
Metoclopramide 2Omg+dexamethasone 4mg 1
Metoclopramide lOmg+dexamethasone 4mg 1
2Regimen (and dose m  mg/m )
Anthracycline 40+cyclophosphamide 500+
vincristine 6
Epirubicin 90-120 3
Mitozantrone 8+methotrexate 30 2
Doxorubicin 50+cyclophosphamide 450 2
Doxorubicin 40+etoposide 100 1
5-FU 750+epirubicin 40+cyclophosphamide 750 1
Table 3.8 Details of previous chemotherapy and 
previous antiemetic therapy in patients 
given GR38032F
subsequent course of treatment this same patient 
experienced transient mild nausea but no vomiting. 
None of the other patients had any nausea, 
retching or vomiting. Side effects reported were 
dryness of mouth in 1 patient, mild diarrhoea in 1 
patient (who had a history of chemotherapy- 
associatied diarrhoea) and mild sedation in 1 
patient.
3.5.3. Discussion
The 4 randomised trials accrued 269 patients 
and provided important information on the efficacy 
of the various antiemetics tested (for summary see 
Table 3.9). Although the majority of these 
patients had tumours other than gastric cancer, 
the findings are relevant to the management of 
this tumour because there is no evidence that 
patients with gastric cancer react in a unique way 
to chemotherapy. For patients receiving cisplatin, 
trials 1 and 3 established the superiority of high 
dose metoclopramide over other antiemetics. In 
trial 3 metoclopramide was combined with 
intravenous dexamethasone because this combination 
has been shown to be better than metoclopramide 
alone (197). Also, in trial 3 metoclopramide was 
given as a loading dose (2mg/kg) IV followed by a
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Best antiemetic
Trial 1
Cisplatin regimens 
Non-cisplatin regimens
Trial 2
Non-cisplatin regimens 
Trial 3
Cisplatin regimens 
Trial 4
Non-cisplatin regimens
high dose metoclopramide 
chlorpromaz ine
nabilone and 
prochlorperaz ine
high dose metoclopramide 
and dexamethasone
dexamethasone
Table 3.9 Summary of the results of the 4 
randomised antiemetic trials
continuous IV infusion (3mg/kg) because we have 
shown that this is the best way to achieve steady 
state plasma levels of metoclopramide in the 
region of 850-1000mg/ml (198) - the level at which 
metoclopramide functions optimally as an 
antiemetic (199). Therefore, at the present time 
for patients receiving cisplatin alone or in 
combination with other cytotoxic drugs we would 
recommend the use of high dose metoclopramide and 
dexamethasone.
However, these findings did not apply to the 
cisplatin analogue carboplatin. The group of 
patients who received carboplatin had an overall 
preference for nabilone and prochlorperazine. This 
preference was not based upon superior antiemetic 
efficacy. It was due to the oral route being the 
preferred method of receiving antiemetic therapy 
by these patients. This presumably reflects the 
fact that carboplatin is given as a short IV 
infusion and cisplatin is given as a prolonged IV 
infusion with IV fluids. Thus, the route of 
administration of antiemetic therapy is irrelevant 
to the patient on cisplatin but is extremely 
important to the patient on carboplatin.
With regard to the patients who were given 
chemotherapy regimens which did not include 
cisplatin the best antiemetics appeared to be
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dexamathasone and the combination of nabilone and 
prochlorperazine. The mechanism by which dexameth­
asone is antiemetic is unknown but our experience 
would suggest it is very effective with few 
associated side effects. Nabilone is a semi­
synthetic cannabinoid and when combined with 
prochlorperazine it is an extremely useful 
antiemetic treatment. Sedation and dry mouth are 
the most frequent side effects and these may be 
reduced in frequency by using a slightly lower 
dose of nabilone (lmg bd). Prochlorperazine was 
combined with nabilone to reduce the incidence of 
adverse effects on the central nervous system 
related to nabilone. It has been shown that 
combining a phenothiazine with the naturally 
occurring cannabinoid delta-9-tetrahydrocannabinol 
(THC), reduces the incidence of CNS side effects 
related to THC (200). Our double blind trial 
indicates that this effect occurs when a 
phenothiazine is combined with nabilone.
The dopamine antagonist, metoclopramide, 
when given in low dose (20mg tds) was not 
effective in the treatment of emesis caused by 
cytotoxic drugs, and yet in high dose it was. At 
these higher dosage levels metoclopramide 
antagonises 5HT at the 5-HT3 receptor and it has 
been suggested that this might be one of the ways
127
in which metoclopramide is antiemetic against 
cytotoxic drugs (201). Using an animal model of 
cytotoxic drug induced vomiting the 5-HT3 receptor 
antagonist, GR38032F, was shown to be a potent 
antiemetic (202). Our clinical trial confirms 
these results. Moreover, GR38032F was effective in 
patients who had failed conventional antiemetic 
treatment and its use was assosciated with very 
few side effects.These findings suggests that this 
compound and other 5-HT3 receptor antagonists will 
have an important role in the future management of 
the nausea and vomiting induced by cytotoxic 
drugs.
With the advent of better antiemetic 
treatments, effective palliation with chemotherapy 
of the common solid tumours, including gastric 
cancer, should become more realistic. Chemotherapy 
which produces objective tumour regression in only 
50% of cases will be of more clinical value 
because it can be administered with the minimum of 
side effects.
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CHAPTER FOUR
THE
SUBRENAL CAPSULE ASSAY 
AS A MEANS OF PREDICTING
RESPONSE TO CHEMOTHERAPY
4.1 INTRODUCTION
The six day subrenal capsule (SRC) assay was 
developed by Bogden et al (203) as an in vivo 
xenograft system that could be used to investigate 
the effects of cytotoxic agents on a variety of 
human tumours from xenografts established in nude 
mice, and on primary surgical explants of human 
tumours (204). The technique involves the 
establishment of a first generation xenograft by 
means of transplantation of fresh human tumour (or 
tumour from a xenograft) under the renal capsule 
of normal immunocompetent mice. Initially, nude 
mice were used as the recipients of the tumour but 
later it was shown that it was possible to use 
normal immunocompetent mice (205). It was also 
shown that the growth rate of the xenografts could 
be inhibited by the administration of cytotoxic 
drugs to the mice, and that the degree of growth 
inhibition provided a precise in vivo method of 
measuring the sensitivity of the transplanted 
tumour to the administered cytotoxic drug (205). 
Also, because the technique involved the use of 
immunocompetent mice, rather than immunodeficient 
athymic nude mice, transplatation was possible 
without the creation of a highly sterile 
environment. These factors indicated that the SRC
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assay should be very cost effective and the short 
time frame of the assay was seen as a major 
advantage when compared to the time taken to grow 
xenografts subcutaneously in nude mice. In 
addition, the use of intact solid tumour 
fragments was considered to have greater 
biological relevance than other systems such as 
the in vitro human cloning assay of Hamburger and 
Salmon (206)
As outlined in Chapter Three, chemotherapy 
regimens will usually produce objective tumour 
regression in only 30-45% of patients. 
Nevertheless, those patients who respond to 
chemotherapy benefit in terms of survival, but the 
price is the unnecessary toxicity of those who do 
not respond. We therefore felt that this was a 
suitable tumour in which to study a predictive 
chemotherapy system such as the SRC assay. 
Preliminary information from Bogden's group 
suggested that it should be feasible to grow 
primary surgical explants from gastric cancer 
(207), and therefore we initiated a study to 
investigate the possible role of the SRC assay as 
a chemopredictive test in gastric cancer.
131
4.2 MATERIAL AND METHODS
Surgical Explants
Resected specimens were placed immediately
into tissue culture medium No 199 (TC 199) and
taken to the pathology department where a sample
3approximately 1 cm was removed from the primary
3tumour. The tumour was dissected into 4 x 0.5 cm 
pieces and returned to the tissue culture medium 
for transfer to the laboratory. All patients 
received their operation in the centre where the 
laboratory was located, therefore transportation 
time for specimens was minimised. In the labor­
atory the tumour was trimmed of extraneous 
connective tissue and necrotic areas. It was
prepared for transplantation by dissection into
3pieces approximately 1 mm using a template placed 
under a glass petri dish. After dissection, the 
pieces of tissue were put in a separate petri dish 
containing TC 199 and placed on ice. The sizes of 
the cut pieces of tumour were checked using a 
Zeiss stereoscopic microscope with a micrometer 
scale calibrated so that 1 micrometer unit (MU) 
was equivalent to 0.1 mm. Average diameters ranged 
from 10-15 MU. Pieces smaller or larger than this 
were discarded. A specimen was retained for 
histological analysis. The mice (C57BL/6 x DBA/2
132
FI, hybrid) age 14-20 weeks were ear marked, 
weighed, and anaesthetised with diethyl ether. The 
left side of each animal was shaved and wiped with 
a 70% alcohol solution, then an incision was made 
laterally in the region of the left kidney, which 
was subsequently exteriorised (Figure 4.1). An 
incision was made in the renal capsule (Ziegler 
iridectomy knife with a 4 mm blade) and the tumour 
introduced using a trochar (supplied by 
MacCarthy's Surgical Ltd, Dagenham, UK) (Figures 
4. 2 and 4.3 ). The inside of the trochar was made 
wet by placing it in TC 199 before insertion of 
the tissue. Once under the renal capsule (Figures 
4.4 and 4.5) 2 perpendicular diameters of tumour 
were measured using the stereoscopic microscope. 
After measurement the kidney was carefully resited 
in the abdomen, and the incision was closed using 
a stapler gun (Figure 4.6). Each control group had 
5-8 mice and each treatment group had 4-6 mice. 
All surgery was carried out by one operator (David 
Cunningham).
Six days later the mice were sacrificed by 
cervical dislocation, re-weighed and the tumour 
re-measured in situ. An evaluable assay was one in 
which the mean increase in the sum of the 2 
perpendicular diameters was 0.5 MU (which is the 
same criterion used by Bogden et al (203) ) .
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Figure 4. 1 After an incision in the left flank 
the left kidney was exteriorised.
knife
Figure 4.3 The trochar used to introduce tumour 
under the renal capsule
Figure 4.4 The trochar is under the renal capsule 
loaded with tumour
Figure 4.5 The appearance after the tumour has 
been placed in position
Figure 4.6 The incision after closure with 
staples
Thereafter, the tumour bearing kidney was removed 
and put in formal saline.
Chemotherapy
Chemotherapy was given on Days 1,3 and 5 as 
outlined in Table 4.1. The drugs tested were those 
of a 4 drug combination chemotherapy regimen which 
we were using to treat advanced gastric cancer. 
It was proposed that this regimen would be used to 
treat on relapse, patients from whom we had 
obtained tumour tissue for this study at the time 
of initial surgical resection.
Pathology
Sections, prepared from the mouse kidney and 
implanted tumour, were stained with haematoxylin 
and eosin. They were examined by one pathologist 
without the knowledge of the group of origin of 
the specimen (i.e.control or treatment). An 
Inflammation Score was devised in which the degree 
of inflammatory infiltrate was graded as follows: 
none=0, mild=l, moderate=2 and marked=3.
Tumour from an animal allograft and a human 
xenograft
In addition to the tissue from surgical 
implants, tumour was also obtained from a human
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Drug
Dose 
mg/kg/inj ection
Method
Administration
Cisplatin 
Epirubicin 
Methotrexate 
5-Fluorouracil
3.3
6.6
6.6
80.0
Subcutaneous
Intravenous
Subcutaneous
Subcutaneous
Table 4.1 Details of chemotherapy administered 
the mice
xenograft and an animal allograft for 
transplantation. The xenograft was Wils tumour, 
which is a human lung adenocarcinoma established 
in nude mice and the animal allograft was the 
Walker 256 tumour which is a rodent sarcoma grown 
in Wistar rats.
135
4.3 RESULTS
Surgical Explants
Specimens of gastric adenocarcinoma were 
obtained from 17 patients. Sixteen were from the 
primary tumour and 1 was from a lymph node 
metastasis. The specimens retained for 
histological analysis all showed tumour. From the 
17 gastric tumours a total of 418 xenografts were 
transplanted and the mean time for transplantation 
of one xenograft was 4.8 minutes, the mean time 
for tumour resection to completion of 
transplantation was 3hrs 45minutes (range 2hrs 
lOmins - 4hrs 40mins). Fourteen of the 17 tumours 
gave evaluable assays in the control groups with a 
mean increase in the sum of the tumour diameters 
of 4.1 M.U. (range 1.6 - 10.5).
However, when the xenografts were examined 
histologically tumour cells were present in only 
26 (6%) and the remaining xenografts consisted of 
fibrous tissue and a lymphocytic infiltrate. It 
should be emphasised that although a small number 
of xenografts contained tumour, this consisted of 
a few acini or single tumour cells as shown in 
Figure 4.7. The extent to which the xenografts 
were infiltrated by lymphocytes was significantly 
influenced by the administration of cytotoxic
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Figure 4.7 Section of the subrenal capsular 
xenograft six days after implantation. 
A single residual acinus of gastric 
carcinoma is present. This finding was 
exceptional, most animals showing no 
evidence of tumour. (The figure 
appears refractile because of the 
presence of collagen.)(H and E x 753)
drugs. Xenografts from control groups (Figure 
4.8) invariably had a pronounced lymphocytic 
infiltrate compard to treated groups (Figure 4.9). 
These findings were reflected in the Inflammation 
Score which is represented in figure 4.10. There 
was a significantly positive correlation (p<0.001) 
between the Inflammation Score and the increase in 
size of xenografts (Spearman's Rank Correlation). 
In the case of one tumour, rather than giving the 
treatment groups chemotherapy, the animals were 
sacrificed on days 1, 3 and 5 and the tumours were 
examined histologically. This revealed, as might 
be expected, a progressive increase in the amount 
of lymphocytic infiltrate over the 5 day period. 
Also, there was no tumour seen in the transplanted
tissue from day 1, despite the presence of viable
tumour in the specimen which was examined
histologically just before transplantation.
Tumour from the human xenograft and the rodent 
allograft
In both the xenografts there was 
considerable growth over the 6 day period. The 
mean increases in tumour diameters for the Wils 
tumour and the Walker 256 tumour were 11 MU and 65 
MU respectively. Histology of the Wils tumour 
taken from a control and a treatment group is
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B H and E x 40
Figure 4.8 Sections of the xenograft from control 
animals. An intense lymphocytic 
infiltrate is present which extends 
into the renal parenchyma.
B H and E x 48
Figure 4.9 Sections of xenograft from a 5-FU 
treated animal. In contrast to Figure 
4.8 there is no significant 
inflammatoery cell infiltrate.
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Figure 4.10 Inflammation Score for 418 xenografts 
derived from primary surgical 
explants.
shown in Figures 4.11. A typical xenograft from 
the Walker tumour, on day 6, is shown in Figure 
4.12. and the histolgy in Figure 4.13. Histology 
of both xenografts confirmed the increase in 
size was due to tumour. There was persistence of 
the lymphocytic infiltrate but in view of the 
marked tumour growth, this made a negligible 
contribution to the increase in xenograft size.
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A H and E x 40
B H and E x 3 00
Figure 4.11 Sections of the Wils tumour taken from 
a control (A) and treatment group (B).
Figure 4.12 Macroscopic appearance of the Walker 
256 sarcoma six days after trans­
plantation under the renal capsule.
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Figure 4.13 Section of Walker 256 tumour six days 
after subrenal capsular trans­
plantation. Areas of necrosis are 
present, but most of the tumour is
viable. (H and E x 395)
4.4 DISCUSSION
Although the original aim of this study was 
to investigate the usefulness of the SRC assay as 
a chemopredictive test for gastric cancer, it 
became clear from the histological analysis of the 
transplanted xenografts that this would not be 
feasible. However, we have demonstrated a very 
important size artefact related to the 
infiltration of the xenograft by lymphocytes. This 
is disappointing because the SRC assay 
theoretically offers several advantages over other 
chemopredictive systems such as the clonogenic 
assay (206). The SRC assay maintains cell to cell 
contact and does not depend upon the highly 
selective cell population of the clonogenic assay 
in which tumour colonies grown on agar are derived 
from a very small proportion of the original 
tumour (206).
When Bogden et al (205) first introduced the 
SRC assay, it was suggested that the short time 
frame required for tumour growth would render any 
immunological response to the implanted tumour 
irrelevant. Subsequent experience was to the 
contrary; Edelstein et al (208) have shown that 6 
days after transplatation, the tumour is usually 
infiltrated by mouse "response cells".
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Nevertheless, there was still debate about the 
significance of this infiltrate, especially in 
terms of its interference with assessment of the 
assay. Using flow cytometry, Aamdal et al (209) 
demonstrated that for human tumours established in 
nude mice and subsequently transplanted under the 
SRC, that the contribution of the lymphocytic 
infiltrate to the overall volume of the xenograft 
was 15-25%. On the basis of these results they 
concluded that the inflammatory infiltrate was of 
little consequence to the measurement of xenograft 
growth.
For primary surgical explants from gastric 
cancer we have shown conclusively that there is an 
inherent defect within the SRC assay. Apparent 
growth, as a result of lymphocytic infiltration 
occurred in control xenografts which did not 
contain viable tumour cells. The amount of 
lymphocytic infiltration was reduced by 
administration of cytotoxic drugs, so that 
xenografts exposed to cytotoxic drugs were smaller 
than the controls. Using the parameters of tumour 
measurement in this situation is inadvisable, and 
might lead to the erroneous assessment of a 
cytotoxic agent's activity against a given tumour. 
Thus, for tumour derived from primary surgical 
explants, histological validation of the assay is
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essential. Levi et al (210) modified the SRC assay 
to include an histological scoring system which 
encompassed the extent of the tumour necrosis and 
the amount of lymphocytic infiltration. This is 
more reliable than tumour measurement alone, but 
has the disadvantage of making the SRC assay more 
complex, and time consuming to perform.
Despite these findings, Bogden continues to 
report "a high rate of evaluable specimens" 
without reference to histological validation 
(211) and in a recent review article concluded 
"host cellular reactions are not artefactual to a 
tumour size parameter for evaluating tumour 
response" (212). Similarly a recent study from 
France emphasised the value of the SRC assay as a 
chemopredictive test in cervical cancer but made 
no mention of the histology of the xenograft 
(213).
It may be argued that the "take rate" of the 
assay could be improved by only using tissue 
confirmed by frozen section to contain viable 
tumour cells. However, growth of tumour using the 
SRC technique was still unsuccessful in 4 of our 
17 tumours where the presence of viable tumour 
cells was confirmed histologically by frozen 
section prior to transplantation.
Our experience with the transplantation of
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human and animal tumour xenografts under the SRC 
has been limited to 2 tumours, both of which grew 
consistently well within the SRC assay. The growth 
was on such a large scale that routine 
histological validation was not essential and 
provided no obvious advantage over macroscopic 
tumour measurement. Moreover, in this context the 
"size artefact" related to lymphocytic 
infiltration was less relevant. Indeed, we have 
successfully used the SRC assay to investigate 
circumvention of drug resistance with verapamil in 
Wils tumour (214) and to examine low density 
lipoprotein as a cytotoxic drug targeting vehicle 
in the walker 256 tumour (215).
The use of the (SRC) assay as a chemo- 
predictive test in gastric cancer did not prove 
feasible . Important defects within the SRC assay 
were identified. In particular, a lymphocytic 
infiltration of the dead, transplanted tumour 
tissue can produce apparent tumour growth. Thus, 
stricter criteria of tumour growth including 
histological confirmation of viable tumour in the 
transplant are essential to prevent misleading 
results from the SRC assay.
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CONCLUSIONS
In this thesis we have defined the group of 
patients with gastric cancer who do well after 
surgical resection. Patients in whom the tumour 
has penetrated the serosa do badly, even if they 
have an apparently curative resection. For this 
group of patients, surgery alone is insufficient 
treatment and some form of adjuvant therapy is 
clearly required. The best candidate at the moment 
is chemotherapy but so far the results of adjuvant 
chemotherapy have been disappointing. Another 
possible approach involves the use of intra- 
peritoneal chemotherapy given in the adjuvant 
setting because as outlined in Chapter Two, 
tumours which have penetrated the serosa are often 
associated with free cancer cells in the 
peritoneum. Cisplatin, one of the most active 
drugs in gastric cancer, has been given by the 
intraperitoneal route to treat ovarian cancer but 
not gastric cancer. This route of administration 
effectively delivers 15 times the equivalent 
intravenous dose to the peritoneum and because it 
is absorbed via the peritoneum it also has a 
systemic effect (216). This systemic effect would 
be necessary to eradicate micrometastatic disease 
outwith the peritoneum.
The Japanese experience has shown that it is 
possible to improve the prognosis for patients
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with gastric cancer by making an early diagnosis. 
In the U.K. preliminary results from a dyspepsia 
clinic, in which patient groups with an 
accentuated risk of developing gastric cancer are 
screened have been encouraging. If these results 
are confirmed it would be worthwhile establishing 
similar clinics throughout the country.
With regard to advanced disease, further 
trials of chemotherapy are required to determine 
new, active cytotoxic drugs and the best 
combination of cytotoxic drugs for clinical use. 
Promising additions to the list of active single 
agents include ciplatin and triazinate but the 
bench mark remains 5-FU. Outwith clinical trials, 
the patients most likely to benefit from 
chemotherapy are those without liver metastases. 
For some of these patients successful treatment 
may result in sufficient tumour regression that 
will allow the resection of a primary tumour 
initially deemed to be inoperable. Therefore, the 
potential benefits from chemotherapy of this 
subgroup of patients are considerable, 
particularly if side effects of treatment such as 
nausea and vomiting can be abolished, and with 
the new 5-HT3 antagonists this may become 
possible. For the patients with liver metastases, 
regional chemotherapy such as 5-FU given via the
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hepatic artery deserves investigation and could be 
combined with systemic treatment. Other possible 
therapeutic avenues include intra-hepatic 
microspheres (217) which can be used as a vehicle 
for targeting cytotoxic drugs against the tumour. 
There will also be patients for whom immediate 
cytotoxic drug therapy may be inappropriate; for 
example it would be difficult to justify the use 
of chemotherapy in an elderly patient with asympt­
omatic liver metastases. Such a patient should be 
carefully reviewed and only offered chemotherapy 
if the tumour gives rise to sympotoms.
By focusing on these areas eventually it may 
be possible to improve the outlook for our 
patients with gastric cancer. Certainly, there is 
no place for therapeutic nihilism or the remarks 
of Mayo Robson made in 1900 will remain equally 
relevant at the end of this century.
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